1
|
Takimoto R, Kamigaki T, Ito H, Saito M, Takizawa K, Soejima K, Yasuda H, Ohgino K, Terai H, Tomita K, Miura M, Mizukoshi E, Miyashita T, Nakamoto Y, Hayashi K, Miwa S, Kitahara M, Takeuchi A, Kimura H, Mochizuki T, Sugie H, Seino KI, Yamada T, Takeuchi S, Makita K, Naitoh K, Yasumoto K, Yoshida Y, Inoue H, Kotake K, Ohshima K, Noda SE, Okamoto M, Yoshimoto Y, Okada S, Ibe H, Oguma E, Goto S. Safety evaluation of immune-cell therapy for malignant tumor in the Cancer Immune-cell Therapy Evaluation Group (CITEG). Cytotherapy 2023; 25:1229-1235. [PMID: 37486281 DOI: 10.1016/j.jcyt.2023.06.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2023] [Revised: 06/10/2023] [Accepted: 06/22/2023] [Indexed: 07/25/2023]
Abstract
BACKGROUND AIMS With the aim of strengthening the scientific evidence of immune-cell therapy for cancer and further examining its safety, in October 2015, our hospital jointly established the Cancer Immune-Cell Therapy Evaluation Group (CITEG) with 39 medical facilities nationwide. METHODS Medical information, such as patients' background characteristics, clinical efficacy and therapeutic cell types obtained from each facility, has been accumulated, analyzed and evaluated by CITEG. In this prospective study, we analyzed the adverse events associated with immune-cell therapy until the end of September 2022, and we presented our interim safety evaluation. RESULTS A total of 3839 patients with malignant tumor were treated with immune-cell therapy, with a median age of 64 years (range, 13-97 years) and a male-to-female ratio of 1:1.08 (1846:1993). Most patients' performance status was 0 or 1 (86.8%) at the first visit, and 3234 cases (84.2%) were advanced or recurrent cases, which accounted for the majority. The total number of administrations reported in CITEG was 31890, of which 960 (3.0%) showed adverse events. The numbers of adverse events caused by treatment were 363 (1.8%) of 19661 administrations of αβT cell therapy, 9 of 845 administrations of γδT-cell therapy (1.1%) and 10 of 626 administrations of natural killer cell therapy (1.6%). The number of adverse events caused by dendritic cell (DC) vaccine therapy was 578 of 10748 administrations (5.4%), which was significantly larger than those for other treatments. Multivariate analysis revealed that αβT cell therapy had a significantly greater risk of adverse events at performance status 1 or higher, and patients younger than 64 years, women or adjuvant immune-cell therapy had a greater risk of adverse events in DC vaccine therapy. Injection-site reactions were the most frequently reported adverse events, with 449 events, the majority of which were associated with DC vaccine therapy. Among all other adverse events, fever (228 events), fatigue (141 events) and itching (131 events) were frequently reported. In contrast, three patients had adverse events (fever, abdominal pain and interstitial pneumonia) that required hospitalization, although they were weakly related to this therapy; rather, it was considered to be the effect of treatment for the primary disease. CONCLUSIONS Immune-cell therapy for cancer was considered to be a safe treatment without serious adverse events.
Collapse
Affiliation(s)
- Rishu Takimoto
- Seta Clinic Group, Tokyo, Japan; Next Generation Cell and Immunotherapy, Advanced Research Institute for Health Science, Juntendo University, Tokyo, Japan; LSI Sapporo Clinic, Sapporo, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan.
| | - Takashi Kamigaki
- Seta Clinic Group, Tokyo, Japan; Next Generation Cell and Immunotherapy, Advanced Research Institute for Health Science, Juntendo University, Tokyo, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Hisao Ito
- Seta Clinic Group, Tokyo, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Masashi Saito
- Seta Clinic Group, Tokyo, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Ken Takizawa
- Seta Clinic Group, Tokyo, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Kenzo Soejima
- Seta Clinic Group, Tokyo, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Hiroyuki Yasuda
- Seta Clinic Group, Tokyo, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Keiko Ohgino
- Seta Clinic Group, Tokyo, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Hideki Terai
- Seta Clinic Group, Tokyo, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Katsuro Tomita
- Kanazawa Advanced Medical Center, Kanazawa City, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Miyabi Miura
- Kanazawa Advanced Medical Center, Kanazawa City, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Eishiro Mizukoshi
- Kanazawa Advanced Medical Center, Kanazawa City, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Tomoharu Miyashita
- Kanazawa Advanced Medical Center, Kanazawa City, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Yasunari Nakamoto
- Kanazawa Advanced Medical Center, Kanazawa City, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Katsuhiro Hayashi
- Kanazawa Advanced Medical Center, Kanazawa City, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Shinji Miwa
- Kanazawa Advanced Medical Center, Kanazawa City, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Masaaki Kitahara
- Kanazawa Advanced Medical Center, Kanazawa City, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Akihiko Takeuchi
- Kanazawa Advanced Medical Center, Kanazawa City, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Hiroaki Kimura
- Kanazawa Advanced Medical Center, Kanazawa City, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Takafumi Mochizuki
- Kanazawa Advanced Medical Center, Kanazawa City, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Hiroki Sugie
- LSI Sapporo Clinic, Sapporo, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Ken-Ichiro Seino
- LSI Sapporo Clinic, Sapporo, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Tomonori Yamada
- LSI Sapporo Clinic, Sapporo, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Syuhei Takeuchi
- LSI Sapporo Clinic, Sapporo, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Kaori Makita
- Kitaosaka Medical Clinic, Suita City, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Keiko Naitoh
- Fukuoka Medical Clinic, Fukuoka City, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Kosei Yasumoto
- Fukuoka Medical Clinic, Fukuoka City, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Yoichiro Yoshida
- Fukuoka Medical Clinic, Fukuoka City, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Hiroyuki Inoue
- Fukuoka Medical Clinic, Fukuoka City, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Katsuhiro Kotake
- Masuko Memorial Hospital, Nagoya City, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Kihachi Ohshima
- Heisei-Hidaka Clinic, Gunma, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Shin-Ei Noda
- Heisei-Hidaka Clinic, Gunma, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Masahiko Okamoto
- Heisei-Hidaka Clinic, Gunma, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Yuya Yoshimoto
- Heisei-Hidaka Clinic, Gunma, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| | - Sachiko Okada
- Seta Clinic Group, Tokyo, Japan; Next Generation Cell and Immunotherapy, Advanced Research Institute for Health Science, Juntendo University, Tokyo, Japan
| | - Hiroshi Ibe
- Seta Clinic Group, Tokyo, Japan; Next Generation Cell and Immunotherapy, Advanced Research Institute for Health Science, Juntendo University, Tokyo, Japan
| | - Eri Oguma
- Seta Clinic Group, Tokyo, Japan; Next Generation Cell and Immunotherapy, Advanced Research Institute for Health Science, Juntendo University, Tokyo, Japan
| | - Shigenori Goto
- Seta Clinic Group, Tokyo, Japan; Next Generation Cell and Immunotherapy, Advanced Research Institute for Health Science, Juntendo University, Tokyo, Japan; Cancer Immune-cell Therapy Evaluation Group (CITEG), Tokyo, Japan
| |
Collapse
|
2
|
Shutta R, Nishino M, Kawamura A, Ukita K, Nakamura H, Yasumoto K, Tsuda M, Okamoto N, Tanaka A, Matsunaga Y, Yano M, Egami Y, Tanouchi J. Negative impact of ultra-thin strut on neointimal coverage condition within one year after implantation as compared to thin sturt in biogradable-polymer sirorimus eluting stents. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.0319] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
BIOSCIENCE randomized trial which compared biodegradable-polymer sirolimus-eluting stents with ultra-thin (60μm) strut (ultra-thin BP-SES) and durable-polymer everolimus-eluting stents with thin (81μm) strut (thin DP-EES) have reported that definite stent thrombosis within 1 year had more frequently occurred in ultra-thin BP-SES (0.9%) than in thin DP-EES group (0.4%) although it was not statistically significant. It suggests that neointimal coverage after stent implantation within 1 year might be different between ultra-thin BP-SES and thin DP-EES. Recently, two types of biogradable-polymer sirorimus eluting stents, thin (80μm) strut type (thin BP-SES) and ultra-thin (60μm) strut type (ultra-thin BP-SES), can be available in clinical settings.
Purpose
We compared neointimal coverage conditions between ultra-thin BP-SES and thin BP-SES by optical coherence tomography (OCT).
Methods
Consecutive Forty-six patients who underwent 21 ultra-thin BP-SESs or 25 thin BP-SESs implantation were enrolled. We compared incidences of acute coronary syndrome, type B2/C lesion, atherectomy device use, stent size, stent length, maximum inflation pressure, and 8-month follow-up OCT parameters including proportions of uncovered struts (%Uncovered), malapposed struts, (%Mallaposed) and mean neointimal hyperplasia thickness (mean NHT) between the two groups.
Results
%Uncovered and %malapposed were significantly higher and mean NHT was significantly lower in ultra-thin BP-SES than in thin BP-SES (Table). The other parameters were similar between the two groups.
Conclusion
Ultra-thin BP-SES showed worse neointimal coverage as compared to thin BP-SES within 1 year after stent implantation, which may increase stent thrombosis.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- R Shutta
- Osaka Rosai Hospital, Sakai, Osaka, Japan
| | - M Nishino
- Osaka Rosai Hospital, Sakai, Osaka, Japan
| | - A Kawamura
- Osaka Rosai Hospital, Sakai, Osaka, Japan
| | - K Ukita
- Osaka Rosai Hospital, Sakai, Osaka, Japan
| | - H Nakamura
- Osaka Rosai Hospital, Sakai, Osaka, Japan
| | - K Yasumoto
- Osaka Rosai Hospital, Sakai, Osaka, Japan
| | - M Tsuda
- Osaka Rosai Hospital, Sakai, Osaka, Japan
| | - N Okamoto
- Osaka Rosai Hospital, Sakai, Osaka, Japan
| | - A Tanaka
- Osaka Rosai Hospital, Sakai, Osaka, Japan
| | | | - M Yano
- Osaka Rosai Hospital, Sakai, Osaka, Japan
| | - Y Egami
- Osaka Rosai Hospital, Sakai, Osaka, Japan
| | - J Tanouchi
- Osaka Rosai Hospital, Sakai, Osaka, Japan
| |
Collapse
|
3
|
Okamoto N, Shutta R, Yanagawa K, Matsuhiro Y, Nakamura H, Yasumoto K, Tsuda M, Tanaka A, Matsunaga Y, Yano M, Yamato M, Egami Y, Tanouchi J, Nishino M. Real-world clinical impact of external elastic lamina-based stent sizing criteria using optical coherence tomography. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.2470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Introduction
ILUMIEN III trial has reported that non-inferiority of optical coherence tomography (OCT)-guided percutaneous coronary intervention (PCI) to intravascular ultrasound-guided PCI for postprocedural minimum stent area. In the trial, external elastic lamina (EEL)-based stent sizing criteria was introduced, however OCT has limitations including incomplete visualization of EEL in severale lesions.
Purpose
The aim of the study is to investigate real-world clinical impact of EEL-based stent sizing criteria.
Methods
The study included consecutive patients who underwent OCT-guided percutaneous coronary intervention (PCI) for de novo lesions in our institution between September 2016 and April 2018. EEL visibility, mean EEL diameter, mean lumen diameter and plaque morphology were assessed at proximal and distal references. The plaque morphology at references was categorized according to its most prevalent component as follows: normal, fibrous plaque, lipid plaque, and calcified plaque. Both references were divided into 3 groups according to visibility of EEL.
Results
Among 205 lesions, 31 lesions had artifacts at references (16 proximal and 17 distal references). EEL visibility was summarized in a table. Out of 174 lesions with both analyzable references, 111 lesions (63.8%) had >180-degree EEL visibility at both references. Proportion of plaque morphology were significantly different among 3 groups at proximal and distal references as shown in a figure.
Conclusions
EEL-based stent sizing criteria was usable for 63.8% of all the lesions. Vessel size and plaque morphology were significantly associated with EEL visibility.
Proportion of plaque morphology
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- N Okamoto
- Osaka Rosai Hospital, Division of Cardiology, Osaka, Japan
| | - R Shutta
- Osaka Rosai Hospital, Division of Cardiology, Osaka, Japan
| | - K Yanagawa
- Osaka Rosai Hospital, Division of Cardiology, Osaka, Japan
| | - Y Matsuhiro
- Osaka Rosai Hospital, Division of Cardiology, Osaka, Japan
| | - H Nakamura
- Osaka Rosai Hospital, Division of Cardiology, Osaka, Japan
| | - K Yasumoto
- Osaka Rosai Hospital, Division of Cardiology, Osaka, Japan
| | - M Tsuda
- Osaka Rosai Hospital, Division of Cardiology, Osaka, Japan
| | - A Tanaka
- Osaka Rosai Hospital, Division of Cardiology, Osaka, Japan
| | - Y Matsunaga
- Osaka Rosai Hospital, Division of Cardiology, Osaka, Japan
| | - M Yano
- Osaka Rosai Hospital, Division of Cardiology, Osaka, Japan
| | - M Yamato
- Osaka Rosai Hospital, Division of Cardiology, Osaka, Japan
| | - Y Egami
- Osaka Rosai Hospital, Division of Cardiology, Osaka, Japan
| | - J Tanouchi
- Osaka Rosai Hospital, Division of Cardiology, Osaka, Japan
| | - M Nishino
- Osaka Rosai Hospital, Division of Cardiology, Osaka, Japan
| |
Collapse
|
4
|
Yano M, Nishino M, Nakamura H, Matsuhiro Y, Yasumoto K, Tsuda M, Okamoto N, Tanaka A, Matsunaga-Lee Y, Yamato M, Egami Y, Shutta R, Tanouchi J. Difference of myocardial injury, inflammation and early recurrence after pulmonary vein isolation among laser balloon ablation, radiofrequency catheter ablation and cryoballoon ablation. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.0574] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Pulmonary vein isolation (PVI) has become well-established as the main therapy for patients with drug-refractory paroxysmal atrial fibrillation (PAF) and various isolation methods including radiofrequency ablation (RFA), cryoballoon ablation (CBA) and laser balloon ablation (LBA) were available. Pathological findings in each ablation methods such as myocardial injury and inflammation are thought to be different. High sensitive cardiac troponin I (hs-TnI), subunit of cardiac troponin complex, is a sensitive and specific marker of myocardium injury. High-sensitive C-reactive protein (hs-CRP) is a biomarker of inflammation and is elevated following cardiomyocyte necrosis. Relationship between myocardial injury and inflammation after ablation using RFA, CBA and LBA and early recurrence of atrial fibrillation (ERAF) remains unclear.
Methods
We enrolled consecutive PAF patients from Osaka Rosai Atrial Fibrillation (ORAF) registry who underwent PVI from January 2019 to October 2019. We compared the clinical characteristics including age, gender, hypertension, diabetes mellitus, history of heart failure, CHADS2Vasc score, renal function, serum BNP level and echocardiographic parameters including left ventricular dimensions, left atrial diameter (LAD) and left ventricular ejection fraction (LVEF) between RFA, CBA and LBA groups. We investigated the difference of relationship between myocardial injury marker (hs-TnI), inflammation markers (white blood cell change (DWBC) from post to pre PVI, neutrophil-to-lymphocyte ratio change (DNLR) from after to before PVI and hs-CRP) at 36–48 hours after PVI and ERAF (<3 months after PVI) between each group.
Results
We enrolled 187 consecutive PAF patients who underwent PVI. RFA, CBA and LBA groups comprised 108, 57 and 22 patients, respectively. There were no significant differences of age, gender, hypertension, diabetes mellitus, history of heart failure, CHADS2Vasc score, renal function, serum BNP level and echocardiographic parameters between each group. Serum hs-TnI in RFA group and LBA group were significantly lower than in CBA group (2.643 ng/ml vs 5.240ng/ml, 1.344 ng/ml vs 5.240 ng/ml, p<0.001, p=0.002, respectively, Figure). DWBC was significantly higher in LBA group than CBA group (1157.3/μl vs 418.4/μl, p=0.045). DNLR did not differ between each group. Hs-CRP in RFA group and LBA group were significantly higher than in CBA group (1.881 mg/dl vs 1.186 mg/dl, 2.173 mg/dl vs 1.186 mg/dl, p=0.010, p=0.003, respectively, Figure). Incidence of ERAF was significantly higher in LBA group than RFA group (36.4% vs 16.7%, p=0.035). Incidence of ERAF tended to be higher in LBA group than CBA group (36.4% vs 19.3%, p=0.112).
Conclusion
LBA may cause less myocardial injury than RFA and CBA, on the contrary LBA may cause more inflammation than CBA. Incidence of ERAF in LBA was highest between each procedure.
Inflammation markers and ERAF
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- M Yano
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - M Nishino
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - H Nakamura
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - Y Matsuhiro
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - K Yasumoto
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - M Tsuda
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - N Okamoto
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - A Tanaka
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | | | - M Yamato
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - Y Egami
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - R Shutta
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - J Tanouchi
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| |
Collapse
|
5
|
Ukita K, Kawamura A, Nakamura H, Yasumoto K, Tsuda M, Okamoto N, Tanaka A, Matsunaga Y, Yano M, Egami Y, Shutta R, Nishino M, Tanouchi J. Outcome of contact force-guided radiofrequency catheter ablation or second generation cryoballoon ablation for paroxysmal atrial fibrillation: propensity score matched analysis. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.0571] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Little has been reported on the outcome of contact force (CF)-guided radiofrequency catheter ablation (RFCA) and second generation cryoballoon ablation (CBA).
Purpose
The purpose of this study was to compare the outcome of CF-guided RFCA and second generation CBA for paroxysmal atrial fibrillation (PAF).
Methods
We enrolled the consecutive 364 patients with PAF who underwent initial ablation between September 2014 and July 2018 in our hospital. We compared the late recurrence of atrial tachyarrhythmia more than three months after ablation between RFCA group and CBA group. All RFCA procedures were performed using CF-sensing catheter and all CBA procedures were performed using second generation CB.
Results
There were significant differences in background characteristics: chronic kidney disease, serum brain natriuretic peptide level, and left ventricular ejection fraction. After propensity score matched analysis (Table), atrial tachyarrhythmia free survival was significantly higher in CBA group than in RFCA group (Figure).
Conclusions
Second generation CBA showed a significantly lower late recurrence rate compared to CF-guided RFCA.
Kaplan-Meier Curve
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- K Ukita
- Osaka Rosai Hospital, Sakai, Japan
| | | | | | | | - M Tsuda
- Osaka Rosai Hospital, Sakai, Japan
| | | | - A Tanaka
- Osaka Rosai Hospital, Sakai, Japan
| | | | - M Yano
- Osaka Rosai Hospital, Sakai, Japan
| | - Y Egami
- Osaka Rosai Hospital, Sakai, Japan
| | - R Shutta
- Osaka Rosai Hospital, Sakai, Japan
| | | | | |
Collapse
|
6
|
Yano M, Nishino M, Yanagawa K, Nakamura H, Matsuhiro Y, Yasumoto K, Tsuda M, Okamoto N, Tanaka A, Matsunaga-Lee Y, Yamato M, Egami Y, Shutta R, Tanouchi J. Clinical characteristics and outcomes after pulmonary vein isolation in atrial fibrillation patients with complete right bundle branch block. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.0579] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
Background
Complete right bundle branch block (CRBBB) is one of the most frequent alterations of the electrocardiogram (ECG). Several studies have shown that CRBBB was a risk factor for cardiovascular diseases and the appearance of CRBBB in patients hospitalized for exacerbated heart failure (HF) was associated with a worse prognosis. Various alternations of ECG such as early repolarization pattern and intraventricular conduction disturbance were associated with high recurrence ratio of atrial fibrillation (AF) after pulmonary vein isolation (PVI). However clinical outcome after PVI in patients with CRBBB remains unclear.
Methods
We enrolled consecutive AF patients who underwent PVI from September 2014 to November 2018 rom Osaka Rosai Atrial Fibrillation (ORAF) registry. We excluded patients with other wide QRS (left bundle branch block, ventricular pacing and unclassified intraventricular conduction disturbance) and divided into 2 groups; CRBBB (QRS duration ≥120msec) group and no-CRBBB (QRS duration <120) group. We compared the clinical characteristics including age, gender, hypertension, diabetes mellitus, history of heart failure, history of stroke, CHADS2Vasc score, paroxysmal AF (PAF), renal function, plasma brain natriuretic peptide (BNP) level and echocardiographic parameters including left ventricular end-diastolic diameter (LVDd), left ventricular end-systolic diameter (LVDs), left atrial diameter (LAD) and left ventricular ejection fraction (LVEF) between the 2 groups. We also compared the incidence of late recurrence of AF/atrial tachycardia (AT) between the 2 groups. We investigated whether CRBBB was an independent predictor of late recurrence of AF/AT after PVI by multivariate Cox analysis.
Results
We enrolled 736 consecutive AF patients who underwent PVI. CRBBB patients comprised 55 patients (7.5%). There were no significant differences of age, gender, hypertension, diabetes mellitus, history of heart failure, history of stroke, CHADS2Vasc score, PAF, renal function, plasma BNP level and echocardiographic parameters (LVDd, LVDs, LVEF and LAD) between the 2 groups. Incidence of AF/AT recurrence after PVI was significantly higher in CRBBB group than no-CRBBB group (Figure). CRBBB was an independently and significantly associated with late recurrence of AF/AT after PVI by multivariate Cox analysis (hazard ratio: 1.923, 95% CI: 1.190–2.961, p=0.009) in addition to female (p<0.001), no-PAF (p=0.005) and left atrial diameter (p=0.042).
Conclusion
CRBBB may be a strong predictor of AF/AT late recurrence after PVI.
AF/Ar recurrence after PVI
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- M Yano
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - M Nishino
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - K Yanagawa
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - H Nakamura
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - Y Matsuhiro
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - K Yasumoto
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - M Tsuda
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - N Okamoto
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - A Tanaka
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | | | - M Yamato
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - Y Egami
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - R Shutta
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - J Tanouchi
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| |
Collapse
|
7
|
Ichiki Y, Shigematsu Y, Baba T, Shiota H, Fukuyama T, Nagata Y, So T, Yasuda M, Takenoyama M, Yasumoto K. Development of adoptive immunotherapy with KK-LC-1-specific TCR-transduced γδT cells against lung cancer cells. Cancer Sci 2020; 111:4021-4030. [PMID: 32780528 PMCID: PMC7648040 DOI: 10.1111/cas.14612] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2020] [Revised: 08/07/2020] [Accepted: 08/09/2020] [Indexed: 12/11/2022] Open
Abstract
The present study analyzed the antitumor effect of γδT cells transduced with the TCR of cancer-specific CTLs to establish forceful cancer-specific adoptive immunotherapy. We cloned the TCRαβ genes from CTLs showing HLA-B15 restricted recognition of Kita-Kyushu lung cancer antigen-1 (KK-LC-1), a cancer/germline gene antigen, identified in a lung adenocarcinoma case (F1121). The TCRαβ and CD8 genes were transduced into γδT cells induced from PBLs of healthy volunteers stimulated with zoledronate and IL-2. The KK-LC-1-specific TCRαβ-CD8 γδT cells showed cytotoxic activity against the KK-LC-1 positive lung cancer cell line F1121L and produced IFN-γ against F1121L and KK-LC-1 peptide-pulsed F1121 EBV-B cells. These responses were blocked by HLA class I and HLA-B/C antibodies. An in vivo assay using NOD/SCID mice with xenotransplantation of human lung cancer cells was performed, and the TCRαβ-CD8 transduced γδT cells (TCRαβ-CD8 γδT cells) were intravenously injected. Growth inhibition of KK-LC-1+ , HLA-B15+ lung cancer cells was confirmed in mice with injection of the TCRαβ-CD8 γδT cells from 1 wk after xenotransplantation of cancer cells but not in those treated 2 wk after xenotransplantation. The resected specimens of the tumor, 2 wk after xenotransplantation, highly expressed FasL but not programmed death ligand-1 (PD-L1) by immunohistochemical staining. FasL highly expressed cancer cells xenotransplanted 2 wk ago were resistant to TCRαβ-CD8 γδT cells injection. These results suggested that apoptosis of Fas-positive TCRαβ-CD8 γδT cells may be induced by a Fas-mediated signal after interacting with FasL-positive cancer cells.
Collapse
MESH Headings
- Animals
- Antigens, Neoplasm/immunology
- Cell Line, Tumor
- Cytokines/metabolism
- Disease Models, Animal
- Humans
- Immunomodulation
- Immunotherapy, Adoptive
- Lung Neoplasms/etiology
- Lung Neoplasms/metabolism
- Lung Neoplasms/pathology
- Lung Neoplasms/therapy
- Lymphocytes, Tumor-Infiltrating/immunology
- Lymphocytes, Tumor-Infiltrating/metabolism
- Lymphocytes, Tumor-Infiltrating/pathology
- Mice, Transgenic
- Receptors, Antigen, T-Cell, gamma-delta/metabolism
- T-Lymphocyte Subsets/immunology
- T-Lymphocyte Subsets/metabolism
- T-Lymphocytes, Cytotoxic/immunology
- T-Lymphocytes, Cytotoxic/metabolism
- Transduction, Genetic
- Treatment Outcome
- Xenograft Model Antitumor Assays
Collapse
Grants
- Cancer Translational Research Project; Ministry of Health, Labour and Welfare of Japan
- Cancer Research Institute, UOEH Research Grant for Promotion of Occupational Health
- JP20390375 Ministry of Education, Culture, Sports, Science and Technology, Japan
- JP21659327 Ministry of Education, Culture, Sports, Science and Technology, Japan
- JP18K08806 Ministry of Education, Culture, Sports, Science and Technology, Japan
- JP19K09294 Ministry of Education, Culture, Sports, Science and Technology, Japan
Collapse
Affiliation(s)
- Yoshinobu Ichiki
- Department of General Thoracic SurgeryNational Hospital Organization, Saitama HospitalWakoJapan
- Second Department of SurgerySchool of MedicineUniversity of Occupational and Environmental HealthKitakyushuJapan
| | - Yoshiki Shigematsu
- Second Department of SurgerySchool of MedicineUniversity of Occupational and Environmental HealthKitakyushuJapan
- Department of Respiratory SurgeryIchinomiya‐Nishi HospitalIchinomiyaJapan
| | - Tetsuro Baba
- Second Department of SurgerySchool of MedicineUniversity of Occupational and Environmental HealthKitakyushuJapan
- Baba ClinicKasuya‐gunJapan
| | - Hironobu Shiota
- Second Department of SurgerySchool of MedicineUniversity of Occupational and Environmental HealthKitakyushuJapan
- Department of General Thoracic SurgeryChiba Rosai HospitalIchiharaJapan
| | - Takashi Fukuyama
- Second Department of SurgerySchool of MedicineUniversity of Occupational and Environmental HealthKitakyushuJapan
- Division of Biomedical ResearchKitasato University Medical CenterKitamotoJapan
| | - Yoshika Nagata
- Second Department of SurgerySchool of MedicineUniversity of Occupational and Environmental HealthKitakyushuJapan
- Department of Breast SurgeryShonan Kamakura General HospitalKamakuraJapan
| | - Tetsuya So
- Second Department of SurgerySchool of MedicineUniversity of Occupational and Environmental HealthKitakyushuJapan
- Department of Thoracic SurgeryShin‐Komonji HospitalKitakyusyuJapan
| | - Manabu Yasuda
- Second Department of SurgerySchool of MedicineUniversity of Occupational and Environmental HealthKitakyushuJapan
- Department of Chest SurgeryIizuka HospitalIizukaJapan
| | - Mitsuhiro Takenoyama
- Second Department of SurgerySchool of MedicineUniversity of Occupational and Environmental HealthKitakyushuJapan
- Department of Thoracic OncologyNational Hospital Organization Kyushu Cancer CenterFukuokaJapan
| | - Kosei Yasumoto
- Second Department of SurgerySchool of MedicineUniversity of Occupational and Environmental HealthKitakyushuJapan
- Kitakyushu Municipal Moji HospitalKitakyushuJapan
| |
Collapse
|
8
|
Yasumoto K, Egami Y, Ukita K, Yanagawa K, Nakamura H, Matsuhiro Y, Tsuda M, Okamoto N, Tanaka A, Matsunaga-Lee Y, Yano M, Yamato M, Shutta R, Nishino M, Tanouchi J. Ablation index guide pulmonary vein isolation can reduce early recurrence of atrial fibrillation: a propensity score-matched analysis. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.0575] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Ablation index (AI) is a novel marker of ablation lesion quality for radiofrequency ablation (RFA). It has been reported that AI guided pulmonary vein isolation (PVI) reduced pulmonary vein reconnection and late recurrence of atrial fibrillation (AF). However, little is known about the impact of AI guided PVI on early recurrence of AF (ERAF).
Purpose
The aim of this study is to clarify whether AI guided PVI can reduce ERAF.
Methods
From September 2014 to August 2019, consecutive AF patients who underwent 1st session PVI were enrolled. We compared prevalence of ERAF between AI guided PVI group (AI group) and conventional contact force guided PVI group (CF group) using propensity score-matched analysis, which adjusted patient backgrounds (age, sex, and body mass index (BMI)), type of AF, the history of heart failure, hypertension, diabetes and stroke, laboratory findings including estimated glomerular filtration rate (eGFR) and b-type natriuretic peptide (BNP), and echocardiographic parameters including left ventricular ejection fraction (LVEF) and left atrial diameter.
Results
Total 711 patients were enrolled. AI group comprised 233 patients and CF group comprised 233 patients. Prevalence of ERAF were significantly lower in AI group than in CF group significantly (21.5% vs 36.1%, p=0.001, Table).
Conclusions
AI guided PVI can reduce ERAF as compared to conventional method.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- K Yasumoto
- Osaka Rosai Hospital, Department of Cardiology, Sakai, Japan
| | - Y Egami
- Osaka Rosai Hospital, Department of Cardiology, Sakai, Japan
| | - K Ukita
- Osaka Rosai Hospital, Department of Cardiology, Sakai, Japan
| | - K Yanagawa
- Osaka Rosai Hospital, Department of Cardiology, Sakai, Japan
| | - H Nakamura
- Osaka Rosai Hospital, Department of Cardiology, Sakai, Japan
| | - Y Matsuhiro
- Osaka Rosai Hospital, Department of Cardiology, Sakai, Japan
| | - M Tsuda
- Osaka Rosai Hospital, Department of Cardiology, Sakai, Japan
| | - N Okamoto
- Osaka Rosai Hospital, Department of Cardiology, Sakai, Japan
| | - A Tanaka
- Osaka Rosai Hospital, Department of Cardiology, Sakai, Japan
| | - Y Matsunaga-Lee
- Osaka Rosai Hospital, Department of Cardiology, Sakai, Japan
| | - M Yano
- Osaka Rosai Hospital, Department of Cardiology, Sakai, Japan
| | - M Yamato
- Osaka Rosai Hospital, Department of Cardiology, Sakai, Japan
| | - R Shutta
- Osaka Rosai Hospital, Department of Cardiology, Sakai, Japan
| | - M Nishino
- Osaka Rosai Hospital, Department of Cardiology, Sakai, Japan
| | - J Tanouchi
- Osaka Rosai Hospital, Department of Cardiology, Sakai, Japan
| |
Collapse
|
9
|
Goto S, Terao Y, Kamigaki T, Takimoto R, Naitoh K, Makita K, Yasumoto K, Okada S, Takizawa K, Yokomichi N, Suzuki N, Takeda S. Adoptive Immune-Cell Therapy for the Treatment of Neuroendocrine Carcinoma of the Uterine Cervix. Anticancer Res 2020; 40:4741-4748. [PMID: 32727800 DOI: 10.21873/anticanres.14475] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2020] [Revised: 06/18/2020] [Accepted: 06/22/2020] [Indexed: 11/10/2022]
Abstract
BACKGROUND/AIM We aimed to investigate the efficacy of immune-cell therapy in terms of the survival of patients with neuroendocrine carcinoma of the uterine cervix (NECC), which lacks standardized therapeutic approaches. PATIENTS AND METHODS We identified 17 patients who were diagnosed as having NECC and treated with immune-cell therapy. The clinical characteristics of these patients were extracted from their records and their overall survival was measured. RESULTS Of the 17 patients, two patients with early-stage NECC without recurrence and three patients with less than four treatments were excluded. The median survival times from the time of diagnosis and from the initial administration of immune-cell therapy were 49.7 and 24.4 months, respectively. The overall survival rates at 1, 2, and 5 years were 63.6%, 38.2%, and 25.5%, respectively. Long-term survival was observed in the patients with distant metastases. CONCLUSION The preliminary results of this retrospective study suggested the potential efficacy of immune-cell therapy for NECC.
Collapse
Affiliation(s)
- Shigenori Goto
- Seta Clinic, Tokyo, Japan .,Department of Next-Generation Cell and Immune Therapy, Juntendo University School of Medicine, Tokyo, Japan
| | - Yasuhisa Terao
- Department of Obstetrics and Gynecology, Juntendo University School of Medicine, Tokyo, Japan
| | - Takashi Kamigaki
- Seta Clinic, Tokyo, Japan.,Department of Next-Generation Cell and Immune Therapy, Juntendo University School of Medicine, Tokyo, Japan
| | - Rishu Takimoto
- Seta Clinic, Tokyo, Japan.,Department of Next-Generation Cell and Immune Therapy, Juntendo University School of Medicine, Tokyo, Japan
| | | | | | | | - Sachiko Okada
- Seta Clinic, Tokyo, Japan.,Department of Next-Generation Cell and Immune Therapy, Juntendo University School of Medicine, Tokyo, Japan
| | | | - Noriyuki Yokomichi
- Department of Obstetrics and Gynecology, St. Marianna University School of Medicine, Kawasaki, Japan
| | - Nao Suzuki
- Department of Obstetrics and Gynecology, St. Marianna University School of Medicine, Kawasaki, Japan
| | - Satoru Takeda
- Department of Obstetrics and Gynecology, Juntendo University School of Medicine, Tokyo, Japan
| |
Collapse
|
10
|
Takimoto R, Kamigaki T, Okada S, Ibe H, Oguma E, Naitoh K, Makita K, Yasumoto K, Goto S. Prognostic Factors for Endometrial and Cervical Cancers of Uterus Treated With Immune-cell Therapy: A Retrospective Study. Anticancer Res 2020; 40:4729-4740. [PMID: 32727799 DOI: 10.21873/anticanres.14474] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2020] [Revised: 06/08/2020] [Accepted: 06/09/2020] [Indexed: 11/10/2022]
Abstract
BACKGROUND/AIM In this retrospective study, we aimed to investigate the efficacy of immune-cell therapy using T lymphocytes activated in vitro with or without dendritic cell vaccination in combination with standard therapies in terms of the survival of patients with advanced or recurrent endometrial and cervical cancers of the uterus. PATIENTS AND METHODS A total of 187 patients with advanced or recurrent uterine cancer were enrolled in this study. The correlation between overall survival and various clinical factors was examined by univariate and multivariate analyses. RESULTS Univariate analysis revealed that the prognosis was improved in uterine cancer patients who received immune-cell therapy without prior chemotherapy or without distant metastasis. Multivariate analysis demonstrated that the absence of prior chemotherapy for endometrial cancer and liver/lung metastasis of cervical cancer are indications for immune-cell therapy. CONCLUSION Survival benefit in uterine cancer patients could be potentially obtained by a combination of immune-cell therapy with other therapies.
Collapse
Affiliation(s)
- Rishu Takimoto
- Seta Clinic Group, Tokyo, Japan .,Department of Next Generation Cell and Immune Therapy, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| | - Takashi Kamigaki
- Seta Clinic Group, Tokyo, Japan.,Department of Next Generation Cell and Immune Therapy, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| | | | | | | | | | | | | | - Shigenori Goto
- Seta Clinic Group, Tokyo, Japan.,Department of Next Generation Cell and Immune Therapy, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| |
Collapse
|
11
|
Yamada T, Yoshida Y, Maeda T, Yoshimatsu G, Aisu N, Yamashita K, Komono A, Kajitani R, Matsumoto Y, Nagano H, Naito K, Yasumoto K, Takimoto R, Kamigaki T, Goto S, Yoshimura F, Sakata N, Kodama S, Hasegawa S. Changes in Immunological Status in Patients With Metastatic Colorectal Cancer Treated With First-line Chemoimmunotherapy. Anticancer Res 2020; 40:4763-4771. [PMID: 32727803 DOI: 10.21873/anticanres.14478] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2020] [Revised: 06/21/2020] [Accepted: 06/22/2020] [Indexed: 11/10/2022]
Abstract
BACKGROUND/AIM Chemoimmunotherapy is a promising treatment for various malignant diseases. In this study, we examined whether first-line chemoimmunotherapy using adoptive immune-cell therapy was effective for metastatic colorectal cancer (mCRC). PATIENTS AND METHODS The therapeutic efficacy and safety of the standard first-line chemoimmunotherapy with adoptive αβ T cell therapy and bevacizumab were assessed using thirty-two patients with mCRC in our hospital. Immunological status after this chemoimmunotherapy was also evaluated. RESULTS The response and disease control rates were 68.8% and 87.5%, respectively. Further, median progression-free and overall survival were 14.2 and 35.3 months. Immunotherapy-associated toxicity was minimal. Significant decrease in the change of monocyte number (p=0.006) and increase in the change of rate of lymphocyte-to-monocyte ratio (p=0.039) were seen in the complete response group. CONCLUSION First-line chemoimmunotherapy with adoptive αβ T cell therapy may be useful for mCRC.
Collapse
Affiliation(s)
- Teppei Yamada
- Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan .,Department of Regenerative Medicine & Transplantation, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | - Yoichiro Yoshida
- Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | - Toshiki Maeda
- Department of Preventive Medicine and Public Health, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | - Gumpei Yoshimatsu
- Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan.,Department of Regenerative Medicine & Transplantation, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | - Naoya Aisu
- Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | - Kanefumi Yamashita
- Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | - Akira Komono
- Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | - Ryuji Kajitani
- Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | - Yoshiko Matsumoto
- Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | - Hideki Nagano
- Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | | | | | - Rishu Takimoto
- Seta Clinic Group, Tokyo, Japan.,Department of Next Generation Cell and Immune Therapy, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| | - Takashi Kamigaki
- Seta Clinic Group, Tokyo, Japan.,Department of Next Generation Cell and Immune Therapy, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| | - Shigenori Goto
- Seta Clinic Group, Tokyo, Japan.,Department of Next Generation Cell and Immune Therapy, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| | - Fumihiro Yoshimura
- Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | - Naoaki Sakata
- Department of Regenerative Medicine & Transplantation, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | - Shohta Kodama
- Department of Regenerative Medicine & Transplantation, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | - Suguru Hasegawa
- Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| |
Collapse
|
12
|
Takimoto R, Miyashita T, Mizukoshi E, Kamigaki T, Okada S, Ibe H, Oguma E, Naitoh K, Yasumoto K, Makita K, Tomita K, Goto S. Identification of prognostic factors for γδT cell immunotherapy in patients with solid tumor. Cytotherapy 2020; 22:329-336. [PMID: 32303429 DOI: 10.1016/j.jcyt.2020.02.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2019] [Revised: 02/24/2020] [Accepted: 02/25/2020] [Indexed: 11/19/2022]
Abstract
BACKGROUND AIMS Activated γδT cells have been shown to exhibit cytotoxicity against tumor cells. However, the efficacy of γδT cell immunotherapy for a large number of patients with solid tumors remains unclear. In this study, we examined the efficacy of γδT cell immunotherapy using in vitro-activated γδT lymphocytes in combination with standard therapies in terms of the survival of patients with solid tumors, and determined prognostic factor for γδT cell immunotherapy. METHODS 131 patients enrolled in this study received γδT cell immunotherapy with or without standard therapies. Their overall survival was analyzed by the Kaplan-Meier with log-rank test and Cox regression methods. Immunological analysis was performed by flow cytometry (FCM) before and after six cycles of γδT cell immunotherapy. RESULTS Multivariable analysis revealed that patients who showed stable disease (SD) and partial response (PR) to γδT cell immunotherapy showed better prognosis than those with a progressive disease (PD) (P = 0.0269, hazard ratio [HR], 0.410, 95% confidence interval [CI], 0.190-0.901). Furthermore, when immunological parameters were examined by FCM, the high Vγ9/γδT ratio (i.e., the high purity of the Vγ9 cells within the adoptively transferred γδT cells) before treatment was found to be a good prognostic factor for γδT cell immunotherapy (P = 0.0142, HR, 0.328, 95% CI, 0.125-0.801). No serious adverse events were reported during γδT cell immunotherapy. CONCLUSION Thus, γδT cell immunotherapy might extend the survival of patients with solid tumors.
Collapse
Affiliation(s)
- Rishu Takimoto
- Seta Clinic Group, Tokyo, Japan; Department of Next-Generation Cell and Immune Therapy, Juntendo University School of Medicine, Tokyo, Japan.
| | | | - Eishiro Mizukoshi
- Department of Gastroenterology, Graduate School of Medicine, Kanazawa University, Kanazawa, Japan
| | - Takashi Kamigaki
- Seta Clinic Group, Tokyo, Japan; Department of Next-Generation Cell and Immune Therapy, Juntendo University School of Medicine, Tokyo, Japan
| | | | | | | | | | | | | | | | - Shigenori Goto
- Seta Clinic Group, Tokyo, Japan; Department of Next-Generation Cell and Immune Therapy, Juntendo University School of Medicine, Tokyo, Japan
| |
Collapse
|
13
|
Matsuhiro Y, Nishino M, Nakamura H, Yasumoto K, Tanaka A, Nakamura D, Matsunaga Y, Yano M, Yamato M, Egami Y, Shutta R, Tanouti J. P2691Excimer laser coronary angioplasty can achieve favorable clinical outocomes for in-stent restenosis lesion with neoatherosclerosis. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.1009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Recent reports revealed that residual area stenosis (% AS) ≤30% after lesion preparation is a suitable predictor for target lesion revascularization (TLR) after drug-coated balloon (DCB) treatment for in-stent restenosis (ISR). Excimer laser coronary angioplasty (ELCA) can obtain larger lumen area and may be more useful for lesion preparation than plain old ballooning (POBA). On the other hands, it has been reported that in-stent neoatherosclerosis (NA) is major cause of restenosis. It is unclear the correlation between NA of ISR and the effect of ELCA. Thus, we compared the influence of NA which was evaluated by optical coherence tomography (OCT) on % AS for ISR treatment between ELCA and DCB (ELCA) group and POBA and DCB (non-ELCA) group and their clinical outcome.
Methods
We enrolled 58 consecutive ISR lesions which were treated by OCT guidance between July 2014 and July 2018 in our hospital. The lesions were divided into NA and non-NA lesions according to OCT findings. In each lesion, we compared post procedural % AS and % AS change which was calculated by the difference between pre and post procedural % AS between ELCA and non-ELCA groups. In addition, we compared 8-month major advance cardiac events (MACE) defined by composite of binary restenosis and target lesion revascularization (TLR) between ELCA and non-ELCA group in NA lesions.
Results
There were 19 NA (33.3%) and 39 non-NA lesions. In NA lesions, ELCA group can obtain significantly lower % AS (p=0.02) and significantly larger % AS change (p<0.01) than non-ELCA group, but in non-NA lesions, % AS and %AS change were similar between ELCA and non-ELCA groups (table). In 8-month clinical outcome, non-ELCA group experienced MACE twice as much as ELCA group did. (31% vs 17%)
Results of %AS NA lesions (n=19) P value non-NA lesions (n=39) P value ELCA group (n=6) non-ELCA group (n=13) ELCA group (n=17) non-ELCA group (n=22) Post %AS (%) 2±21 26±25 0.02 7±29 23±19 0.07 %AS change (%) 71±15 38±19 <0.01 56±29 44±17 0.11
Conclusion
Although neoatherosclerosis is correlated with refractory restenosis, ELCA can improve residual area stenosis in neoatherosclerosis lesions and can achieve better clinical outcomes for in-stent neoatherosclerosis.
Collapse
Affiliation(s)
| | | | | | | | - A Tanaka
- Osaka Rosai Hospital, Osaka, Japan
| | | | | | - M Yano
- Osaka Rosai Hospital, Osaka, Japan
| | - M Yamato
- Osaka Rosai Hospital, Osaka, Japan
| | - Y Egami
- Osaka Rosai Hospital, Osaka, Japan
| | - R Shutta
- Osaka Rosai Hospital, Osaka, Japan
| | | |
Collapse
|
14
|
Matsuhiro Y, Nishino M, Nakamura H, Yasumoto K, Tanaka A, Nakamura D, Matsunaga Y, Yano M, Yamato M, Egami Y, Shutta R, Tanouti J. P3385Difference of vascular healing after percutaneous coronary intervention between 4 kinds of new generation drug-eluting stents: an optical coherence tomography analysis. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0261] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
New generation drug eluting stents (DES) have improved target vessel failure as compared with early generation DES and bare metal stent. Contemporary several new generation DES are different each other regarding strut thickness and drug and polymer type. A little is known about which stent induces a more favorable vascular healing at follow up.
Purpose
In this study, we compared the vascular healing at 8-month follow up by optical coherence tomography (OCT) between 4 different kinds of new generation DES.
Methods
We enrolled 112 consecutive patients (121 lesions) who underwent PCI using 4 kinds of new generation DES including biodegradable-polymer everolimus-eluting stents (BP-EES), biodegradable-polymer sirolimus-eluting stents (BP-SES), durable-polymer everolimus-eluting stents (DP-EES) and durable-polymer zotarolimus-eluting stents (DP-ZES) and who underwent 8-month follow up angiogram and OCT between July 2016 and April 2018. We compared the OCT parameters including percentage of covered struts, uncovered struts, well-apposed and uncovered struts, malapposed strut and mean neointimal hyperplasia (NIH) thickness between them.
Results
BP-EES consisted of 29 lesions, BP-SES consisted of 25 lesions, DP-EES consisted of 38 lesions and DP-ZES consisted of 29 lesions. A total of 734 frames with 5163 struts in BP-EES, 481 frames with 4214 struts in BP-SES, 783 frames with 6119 struts in DP-EES and 583 frames with 4708 struts in DP-ZES were analyzed. As shown in a table, mean NIH thickness was significantly higher in BP-EES and BP-SES. Thus, we compared the OCT parameters between durable-polymer (DP) group including DP-ZES and DP-EES and biodegradable-polymer (BP) group including BP-EES and BP-SES. The percentage of uncovered struts was significantly lower and mean NIH thickness was significantly higher in BP group than DP group.
Results of OCT parameters BP-EES (n=29) BP-SES (n=25) DP-EES (n=38) DP-ZES (n=29) P value BP group (n=54) DP group (n=67) P value Covered struts (%) 89.5±13.6 92.4±8.6 85.5±17.5 85.0±17.7 0.29 90.9±11.6 85.3±17.4 0.08 Uncovered struts (%) 8.8±10.8 7.1±8.7 14.5±17.5 15.0±17.7 0.14 8.0±9.9 14.7±17.4 0.03 Well-apposed and uncovered struts (%) 7.9±9.9 5.9±7.7 11.7±13.1 12.3±14.0 0.15 7.0±8.9 11.9±13.4 0.04 Malapposed struts (%) 0.8±1.6 1.3±2.2 2.7±5.8 2.7±4.7 0.33 1.0±1.9 2.7±5.3 0.07 Mean NIH thickness (μm) 102±57 121±48 78±28 88±33 <0.01 111±53 82±31 <0.01
Conclusion
The present OCT study demonstrated that delayed neointimal healing characterized by the presence of uncovered struts and lower mean NIH thickness was less common in BP group than DP gruop. Biodegradable-polymer may be more favorable than durable-polymer from the point of view of vascular healing.
Collapse
Affiliation(s)
| | | | | | | | - A Tanaka
- Osaka Rosai Hospital, Osaka, Japan
| | | | | | - M Yano
- Osaka Rosai Hospital, Osaka, Japan
| | - M Yamato
- Osaka Rosai Hospital, Osaka, Japan
| | - Y Egami
- Osaka Rosai Hospital, Osaka, Japan
| | - R Shutta
- Osaka Rosai Hospital, Osaka, Japan
| | | |
Collapse
|
15
|
Matsuhiro Y, Nishino M, Nakamura H, Yasumoto K, Tanaka A, Nakamura D, Matsunaga Y, Yano M, Yamato M, Egami Y, Shutta R, Tanouti J. 103Maximum calcium thickness is a useful predictor for under expansion after post dilatation in calcified lesions: optical coherence tomographic study. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz747.0031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Several reports have revealed that stent under expansion is associated with target lesion failure and calcified lesions usually induced inadequate stent expansion. Contemporary debulking devices such as rotational/orbital atherectomy can modify severe calcified lesions before stenting. However, it is uclear which calcium parameter is most useful predictor for stent expansion in the calcified lesions. Thus, we investigated useful calcium parameters correlating with stent expansion in the calcified lesions.
Methods
We enrolled 43 consecutive calcified lesions (43 patients) who underwent optical coherence tomography (OCT) guided percutaneous coronary intervention (PCI) between September 2016 and January 2019. We evaluated the lesions treated with post dilatation by non-compliant balloon due to stent under expansion after stenting. Exclusion criteria included acute coronary syndrome, in-stent restenosis and lesions without any calcium or treated with rotational atherectomy. If there were several calcium lesions in one patient, we selected maximum calcium angle lesion. Stent expansion defined as post-PCI lumen area divided by the values predicted by the manufactures compliance charts. We compared mean reference area, pre lesion area stenosis, calcium parameters including calcium arc, maximum thickness, area and longitudinal length in pre-PCI OCT evaluations with post-PCI stent expansion at that site.
Results
Maximum calcium thickness showed significant correlation with stent expansion, while the others did not show a significant correlation with stent expansion (table). The optimal thresholds of maximum calcium thickness for the prediction of acceptable stent expansion defined by 80% of the values predicted by the manufactures compliance charts was 870mm (area under curve (AUC): 0.65) (figure).
Results of OCT parameters Univariate analysis P value Mean reference area 0.41 Pre % area stenosis 0.16 Calcium parameters Calcium arc 0.37 Calcium maximum thickness 0.04 Calcium area 0.20 Calcium longitudinal length 0.43
Conclusion
A maximum calcium thickness<870mm is a useful predictor for acceptable stent expansion after post dilatation in calcified lesions.
Collapse
Affiliation(s)
| | | | | | | | - A Tanaka
- Osaka Rosai Hospital, Osaka, Japan
| | | | | | - M Yano
- Osaka Rosai Hospital, Osaka, Japan
| | - M Yamato
- Osaka Rosai Hospital, Osaka, Japan
| | - Y Egami
- Osaka Rosai Hospital, Osaka, Japan
| | - R Shutta
- Osaka Rosai Hospital, Osaka, Japan
| | | |
Collapse
|
16
|
Kawamura A, Nishino M, Matsuhiro Y, Nakamura Z, Yasumura K, Yasumoto K, Tanaka A, Matsunaga Y, Nakamura D, Yano M, Yamato M, Egami Y, Syutta R, Tanouchi Z. P3393Comparison of intermediate-term vascular response to new-generation biodegradable polymer and durable polymer-based drug-eluting stents: optical coherence tomographic study. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0269] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Over the last decade, drug-eluting stents (DES) have undergone substantial modifications with thinner struts and more biocompatible durable polymer (DP) or biodegradable polymer (BP). In DP-based DES, after drug elusion has been completed, DP remnants may trigger of local inflammatory vascular reactions and promote delayed healing, leading to accelerated neoatherosclerosis (NA). Thus, BPs have been developed to reduce the above-mentioned risks. Recently, poor strut coverage and in-stent NA are increasingly recognized the cause of late stent failure, but it is unclear whether BPs can reduce the incidence of NA and the poor stent coverage as compared to DPs.
Objectives
The purpose of this study was to compare the incidence of NA and the stent coverage using optical coherence tomography (OCT) between the DPs and the BPs.
Methods
Between July 2016 and April 2018, 127 consecutive patients with new-generation DES who underwent 8-month follow up OCT imaging were enrolled. Patients were divided into the two groups: DP group who had the new-generation durable polymer everolimus-eluting and zotarolimus-eluting stents and BP group who had the new-generation biodegradable polymer sirolimus-eluting and everolimus-eluting stents. We compared patient characteristics including hypertension, dyslipidemia and diabetes mellitus and 8-month follow up OCT findings including NA, uncovered struts and malapposed struts between the two groups.
Results
The DP group comprised 64 patients (50.4%. The incidence of NA, uncovered struts and malapposed struts were similar between the two groups (DPs vs BPs, 1.56% vs 7.94%, P=0.11; 7.80% vs 5.88%, P=0.16 and 2.76% vs 2.01%, P=0.43, respectively) (table). The other parameters were also similar between the two groups.
Table 1 DP group (n=64) BP group (n=63) P value Hypertension 44 (68.8%) 50 (79.4%) 0.2251 Dyslipidemia 39 (60.9%) 37 (58.7%) 0.8573 Diabetes mellitus 25 (39.1%) 30 (47.6%) 0.3731 8 month OCT follow up findings Neoatherosclerosis 1 (1.6%) 5 (7.9%) 0.1147 Uncovered struts 7.8% (2.8–20.4) 5.9% (0.7–16.7) 0.1616 Malapposed struts 0.2% (0–2.8) 0% (0–2.8) 0.4392
Conclusions
The new-generation DP based-DES may have similar effects on vascular response compared to the new-generation BP-based DES during 8-month follow-up period.
Collapse
Affiliation(s)
| | | | | | | | | | | | - A Tanaka
- Osaka Rosai Hospital, Sakai, Japan
| | | | | | - M Yano
- Osaka Rosai Hospital, Sakai, Japan
| | - M Yamato
- Osaka Rosai Hospital, Sakai, Japan
| | - Y Egami
- Osaka Rosai Hospital, Sakai, Japan
| | - R Syutta
- Osaka Rosai Hospital, Sakai, Japan
| | | |
Collapse
|
17
|
Yanagawa K, Nishino M, Nishino M, Nakamura H, Nakamura H, Matsuhiro Y, Matsuhiro Y, Yasumoto K, Yasumoto K, Tanaka A, Tanaka A, Matsunaga Y, Matsunaga Y, Nakamura D, Nakamura D, Yano M, Yano M, Yamato M, Yamato M, Egami Y, Egami Y, Shutta R, Shutta R, Tanouchi J, Tanouchi J. P2689Irregular protrusion area is associated with incidence of cardiac events after implantation of new generation drug-eluting stents - optical coherence tomography study. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.1007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Several studies using optical coherence tomography (OCT) have shown that the prevalence of irregular protrusion was associated with the incidence of adverse cardiac events. However, the correlation between cardiac events and protrusion area is not well investigated.
Method
One hundred twenty-nine consecutive patients with 138 clesions with 2nd and 3rd generation drug-eluting stents (DES) which had pre-stenting and post-stenting OCT imaging between April 2016 and April 2018 were evaluated. We compared baseline characteristics, procedure findings and OCT findings including minimum stent area, protrusion type and maximum protrusion area between target lesion revascularization (TLR) group and non-TLR group.
Results
TLR occurred in 12 (9.3%) in 129 patients. The baseline characteristics and procedure findings were similar between TLR group and non-TLR group. Univariate analysis revealed that maximum irregular protrusion area was significantly larger (0.51 [0.00–0.63] vs 0.00 [0.00–0.27], p=0.036) in TLR group than non-TLR group. Receiver operating characteristic curve analysis revealed that the suitable cutoff value of maximum irregular protrusion area were 0.43mm2 for TLR. In multivariate analysis using the parameters with p value<0.10 determined by univariate analysis, maximum irregular protrusion (≥0.43mm2) and minimum stent area (MSA) were independently correlated with TLR (table).
Odd's ratio (95% CI) P value Major irregular protrusion (≥0.43mm2) 17.3 (3.63–82.6) <0.001 MSA 2.13 (1.15–3.93) 0.002
Conclusion
Major irregular protrusion (>0.43mm2) in post-stenting OCT findings may be a powerful predictor of TLR in the patients with new generation DES.
Collapse
Affiliation(s)
- K Yanagawa
- Osaka Rosai Hospital, Cardiology, Sakai, Japan
| | - M Nishino
- Osaka Rosai Hospital, Cardiology, Sakai, Japan
| | - M Nishino
- Osaka Rosai Hospital, Cardiology, Sakai, Japan
| | - H Nakamura
- Osaka Rosai Hospital, Cardiology, Sakai, Japan
| | - H Nakamura
- Osaka Rosai Hospital, Cardiology, Sakai, Japan
| | - Y Matsuhiro
- Osaka Rosai Hospital, Cardiology, Sakai, Japan
| | - Y Matsuhiro
- Osaka Rosai Hospital, Cardiology, Sakai, Japan
| | - K Yasumoto
- Osaka Rosai Hospital, Cardiology, Sakai, Japan
| | - K Yasumoto
- Osaka Rosai Hospital, Cardiology, Sakai, Japan
| | - A Tanaka
- Osaka Rosai Hospital, Cardiology, Sakai, Japan
| | - A Tanaka
- Osaka Rosai Hospital, Cardiology, Sakai, Japan
| | - Y Matsunaga
- Osaka Rosai Hospital, Cardiology, Sakai, Japan
| | - Y Matsunaga
- Osaka Rosai Hospital, Cardiology, Sakai, Japan
| | - D Nakamura
- Osaka Rosai Hospital, Cardiology, Sakai, Japan
| | - D Nakamura
- Osaka Rosai Hospital, Cardiology, Sakai, Japan
| | - M Yano
- Osaka Rosai Hospital, Cardiology, Sakai, Japan
| | - M Yano
- Osaka Rosai Hospital, Cardiology, Sakai, Japan
| | - M Yamato
- Osaka Rosai Hospital, Cardiology, Sakai, Japan
| | - M Yamato
- Osaka Rosai Hospital, Cardiology, Sakai, Japan
| | - Y Egami
- Osaka Rosai Hospital, Cardiology, Sakai, Japan
| | - Y Egami
- Osaka Rosai Hospital, Cardiology, Sakai, Japan
| | - R Shutta
- Osaka Rosai Hospital, Cardiology, Sakai, Japan
| | - R Shutta
- Osaka Rosai Hospital, Cardiology, Sakai, Japan
| | - J Tanouchi
- Osaka Rosai Hospital, Cardiology, Sakai, Japan
| | - J Tanouchi
- Osaka Rosai Hospital, Cardiology, Sakai, Japan
| |
Collapse
|
18
|
Yano M, Nishino M, Nakamura H, Matsuhiro Y, Yasumura K, Yasumoto K, Tanaka A, Nakamura D, Matsunaga-Lee Y, Yamato M, Egami Y, Shutta R, Tanouchi J. P1914Relationship between myocardial injury, inflammation and early, late recurrence after pulmonary vein isolation may be different between radiofrequency catheter ablation and cryoballoon ablation. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.0661] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
High sensitive cardiac troponin I (hs-TnI), subunit of cardiac troponin complex, is a sensitive and specific marker of myocardium injury as troponin T. Several studies showed hs-TnI was associated with worse cardiovascular outcomes but relationship between serum hs-TnI level in patients with atrial fibrillation (AF) after pulmonary vein isolation (PVI) and AF recurrence remains unclear.
Methods
We enrolled 444 consecutive AF patients who underwent PVI from May 2017 to September 2018. We investigated the difference of relationship between serum hs-TnI, inflammation markers at 48 hours after PVI and early or late recurrence of AF (ERAF, <3 months and LRAF, during 1 year after PVI in patients with AF) between radiofrequency ablation (RFA) group and cryoballoon ablation (CBA) group.
Results
RFA and CBA were performed in 328 and 116 patients, respectively. There were no significant differences in patient characteristics between RFA group and CBA group. Serum hs-TnI in RFA group was significantly lower than in CBA group (1.93 ng/ml±3.28 vs 5.08 ng/ml±4.29, p<0.001), while hs-CRP was significantly higher in RFA group than CB group (1.97±2.38 mg/dl vs 1.10±0.84 mg/dl, p<0.001). The incidence of ERAF was similar between the two groups (RFA group: 26.8% and CBA group: 21.6%, p=0.262). There was no significant difference of hs-TnI and hs-CRP between patients with ERAF and without ERAF (table). In 213 patients who were followed during 1 year (PVIs were performed from May 2017 to January 2018, RFA 149 and CBA 64 patients), there was no significant association between hs-TnI, hs-CRP and incidence of LRAF (table).
TnI and CRP between RFA and CBA RFA (n=328) CBA (n=116) P value hs-TnI 1.93±3.28 5.08±4.29 <0.001 hs-CRP 1.97±2.38 1.10±0.84 <0.001 3 months follow-up RFA (n=328) CBA (n=116) ERAF (+) ERAF (−) P value ERAF (+) ERAF (−) P value hs-TnI 1.68±1.90 2.02±3.66 0.410 5.03±3.17 5.10±4.56 0.943 hs-CRP 2.23±2.65 1.88±2.27 0.238 1.01±0.84 1.13±0.85 0.524 1 year follow-up RFA (n=149) CBA (n=64) LRAF (+) LRAF (−) P value LRAF (+) LRAF(−) P value hs-TnI 1.61±1.77 1.87±2.69 0.570 4.71±2.14 5.60±5.69 0.664 hs-CRP 2.18±2.24 1.92±2.24 0.550 1.12±0.64 1.12±0.98 0.991
Conclusion
CBA may cause more myocardial injury than RFA, on the contrary RFA may cause more inflammation than CBA. These markers did not affect ERAF and LRAF after PVI.
Collapse
Affiliation(s)
- M Yano
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - M Nishino
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - H Nakamura
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - Y Matsuhiro
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - K Yasumura
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - K Yasumoto
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - A Tanaka
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - D Nakamura
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | | | - M Yamato
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - Y Egami
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - R Shutta
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - J Tanouchi
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| |
Collapse
|
19
|
Matsuhiro Y, Nisino M, Nakamura H, Yasumoto K, Tanaka A, Nakamura D, Matsunaga Y, Yano M, Yamato M, Egami Y, Syutta R, Tanouti J. P1736A novel calcium parameter, calcium ratio, can predict minimum lumen area in calcified lesions: optical coherence tomographic study. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.0490] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Several reports have revealed that minimum lumen area (MLA) is associated with target lesion failure even with newer-generation drug-eluting stents, and calcified lesions usually induced inadequate lumen area because of stent under expansion. Contemporary debulking devices such as rotational/orbital atherectomy can modify severe calcified lesions before stenting. However, there are no optimal criteria to indicate necessity for calcium modification to obtain adequate acute gain. Therefore, we investigated useful calcium parameters correlating with MLA in the calcified lesions after stenting.
Methods
We enrolled 71 consecutive calcified lesions (71 patients) who underwent optical coherence tomography (OCT) guided percutaneous coronary intervention (PCI) between September 2016 and January 2019. Exclusion criteria included acute coronary syndrome, in-stent restenosis and lesions without any calcium or treated with rotational atherectomy. If there were several calcium lesions in one patient, we selected maximum calcium angle lesion. We compared mean reference area, pre lumen area and various calcium parameters including calcium arc, maximum thickness, depth, area, longitudinal length and calcium ratio that was maximum calcium thickness divided by nearest reference diameter in disease-free segments as much as possible in pre-PCI OCT evaluation with post-PCI lumen area at that site by simple and multiple regression analysis.
Results
Calcium ratio was an independent predictor for post-PCI lumen area in addition to mean reference area, while the others were not associated with post-PCI lumen area (table).
Results of OCT parameters Univariate analysis Multivariate analysis P value P value β Mean reference area <0.01 <0.01 0.69 Pre lumen area <0.01 0.08 0.15 Cacium arc <0.01 0.58 −0.06 Calcium maximum thickness 0.62 Calcium ratio <0.01 0.01 −0.21 Calcium area 0.02 0.64 0.05 Calcium longitudinal length 0.60 Calcium depth 0.09
Conclusion
The novel calcium measurement, calcium ratio, may be a useful predictor for post-PCI lumen area for calcified lesions.
Collapse
Affiliation(s)
| | - M Nisino
- Osaka Rosai Hospital, Osaka, Japan
| | | | | | - A Tanaka
- Osaka Rosai Hospital, Osaka, Japan
| | | | | | - M Yano
- Osaka Rosai Hospital, Osaka, Japan
| | - M Yamato
- Osaka Rosai Hospital, Osaka, Japan
| | - Y Egami
- Osaka Rosai Hospital, Osaka, Japan
| | - R Syutta
- Osaka Rosai Hospital, Osaka, Japan
| | | |
Collapse
|
20
|
Yano M, Nishino M, Yasunaga M, Yanagawa K, Nakamura H, Matsuhiro Y, Yasumura K, Yasumoto K, Tanaka A, Mori N, Nakamura D, Egami Y, Shutta R, Tanouchi J. P972Relationship between myocardial injury and early recurrence after pulmonary vein isolation in radiofrequency catheter ablation and cryoballoon ablation. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy564.p972] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- M Yano
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - M Nishino
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - M Yasunaga
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - K Yanagawa
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - H Nakamura
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - Y Matsuhiro
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - K Yasumura
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - K Yasumoto
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - A Tanaka
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - N Mori
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - D Nakamura
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - Y Egami
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - R Shutta
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - J Tanouchi
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| |
Collapse
|
21
|
Nakamura D, Nishino M, Ukita K, Yanagawa K, Yasunaga M, Nakamura H, Matsuhiro Y, Yasumura K, Yasumoto K, Tanaka A, Mori N, Yano M, Egami Y, Shutta R, Tanouchi J. P5527Unique stent design with continuous cobalt wire can avoid protruding immediately after percutaneous coronary intervention compared to classical tubed stent. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.p5527] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- D Nakamura
- Osaka Rosai Hospital, Division of Cardiology, Sakai, Japan
| | - M Nishino
- Osaka Rosai Hospital, Division of Cardiology, Sakai, Japan
| | - K Ukita
- Osaka Rosai Hospital, Division of Cardiology, Sakai, Japan
| | - K Yanagawa
- Osaka Rosai Hospital, Division of Cardiology, Sakai, Japan
| | - M Yasunaga
- Osaka Rosai Hospital, Division of Cardiology, Sakai, Japan
| | - H Nakamura
- Osaka Rosai Hospital, Division of Cardiology, Sakai, Japan
| | - Y Matsuhiro
- Osaka Rosai Hospital, Division of Cardiology, Sakai, Japan
| | - K Yasumura
- Osaka Rosai Hospital, Division of Cardiology, Sakai, Japan
| | - K Yasumoto
- Osaka Rosai Hospital, Division of Cardiology, Sakai, Japan
| | - A Tanaka
- Osaka Rosai Hospital, Division of Cardiology, Sakai, Japan
| | - N Mori
- Osaka Rosai Hospital, Division of Cardiology, Sakai, Japan
| | - M Yano
- Osaka Rosai Hospital, Division of Cardiology, Sakai, Japan
| | - Y Egami
- Osaka Rosai Hospital, Division of Cardiology, Sakai, Japan
| | - R Shutta
- Osaka Rosai Hospital, Division of Cardiology, Sakai, Japan
| | - J Tanouchi
- Osaka Rosai Hospital, Division of Cardiology, Sakai, Japan
| |
Collapse
|
22
|
Yanagawa K, Nishino M, Ukita K, Yasunaga M, Nakamura H, Matsuhiro Y, Yasumura K, Yasumoto K, Tanaka A, Mori N, Nakamura D, Yano M, Egami Y, Shutta R, Tanouchi J. P4739Which factors were correlated with improvement of cardiac function in acute heart failure patients with mid-range ejection fraction? Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.p4739] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- K Yanagawa
- Osaka Rosai Hospital, Cardiology, Sakai, Japan
| | - M Nishino
- Osaka Rosai Hospital, Cardiology, Sakai, Japan
| | - K Ukita
- Osaka Rosai Hospital, Cardiology, Sakai, Japan
| | - M Yasunaga
- Osaka Rosai Hospital, Cardiology, Sakai, Japan
| | - H Nakamura
- Osaka Rosai Hospital, Cardiology, Sakai, Japan
| | - Y Matsuhiro
- Osaka Rosai Hospital, Cardiology, Sakai, Japan
| | - K Yasumura
- Osaka Rosai Hospital, Cardiology, Sakai, Japan
| | - K Yasumoto
- Osaka Rosai Hospital, Cardiology, Sakai, Japan
| | - A Tanaka
- Osaka Rosai Hospital, Cardiology, Sakai, Japan
| | - N Mori
- Osaka Rosai Hospital, Cardiology, Sakai, Japan
| | - D Nakamura
- Osaka Rosai Hospital, Cardiology, Sakai, Japan
| | - M Yano
- Osaka Rosai Hospital, Cardiology, Sakai, Japan
| | - Y Egami
- Osaka Rosai Hospital, Cardiology, Sakai, Japan
| | - R Shutta
- Osaka Rosai Hospital, Cardiology, Sakai, Japan
| | - J Tanouchi
- Osaka Rosai Hospital, Cardiology, Sakai, Japan
| |
Collapse
|
23
|
Yano M, Nishino M, Yasunaga M, Yanagawa K, Nakamura H, Matsuhiro Y, Yasumura K, Yasumoto K, Tanaka A, Mori N, Nakamura D, Egami Y, Shutta R, Tanouchi J. P1897Impact of gender difference on clinical characteristics and late recurrence in patients with small left atrium after pulmonary vein isolation. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.p1897] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- M Yano
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - M Nishino
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - M Yasunaga
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - K Yanagawa
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - H Nakamura
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - Y Matsuhiro
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - K Yasumura
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - K Yasumoto
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - A Tanaka
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - N Mori
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - D Nakamura
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - Y Egami
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - R Shutta
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| | - J Tanouchi
- Osaka Rosai Hospital, Division of cardiology, Sakai, Japan
| |
Collapse
|
24
|
Yasumura K, Syutta R, Yasumoto K, Tanaka A, Mori N, Nakamura D, Yano M, Egami Y, Nishino M, Tanouchi J. P2774Comparison of coronary angioscopic findings after stent implantation among 2 kinds of novel biodegradable polymer-coated and one durable polymer-coated drug-eluting stent. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.p2774] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- K Yasumura
- Osaka Rosai Hospital, division of cardiology, Osaka, Japan
| | - R Syutta
- Osaka Rosai Hospital, division of cardiology, Osaka, Japan
| | - K Yasumoto
- Osaka Rosai Hospital, division of cardiology, Osaka, Japan
| | - A Tanaka
- Osaka Rosai Hospital, division of cardiology, Osaka, Japan
| | - N Mori
- Osaka Rosai Hospital, division of cardiology, Osaka, Japan
| | - D Nakamura
- Osaka Rosai Hospital, division of cardiology, Osaka, Japan
| | - M Yano
- Osaka Rosai Hospital, division of cardiology, Osaka, Japan
| | - Y Egami
- Osaka Rosai Hospital, division of cardiology, Osaka, Japan
| | - M Nishino
- Osaka Rosai Hospital, division of cardiology, Osaka, Japan
| | - J Tanouchi
- Osaka Rosai Hospital, division of cardiology, Osaka, Japan
| |
Collapse
|
25
|
Fukuyama T, Futawatari N, Yamamura R, Yamazaki T, Ichiki Y, Ema A, Ushiku H, Nishi Y, Takahashi Y, Otsuka T, Yamazaki H, Koizumi W, Yasumoto K, Kobayashi N. Expression of KK-LC-1, a cancer/testis antigen, at non-tumour sites of the stomach carrying a tumour. Sci Rep 2018; 8:6131. [PMID: 29666402 PMCID: PMC5904109 DOI: 10.1038/s41598-018-24514-9] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2017] [Accepted: 03/27/2018] [Indexed: 02/07/2023] Open
Abstract
Kita-Kyushu lung cancer antigen-1 (KK-LC-1) is a cancer/testis antigen (CTA) and predominant target for cancer immunotherapy. Our previous study indicated that KK-LC-1 was expressed in 82% of gastric cancers, and also in 79% of early stage of gastric cancers, with a correlation to Helicobacter pylori (H. pylori) infection. In addition, we found that KK-LC-1 was occasionally expressed at non-tumour sites of stomachs carrying tumours. Here, we investigated the characteristics of KK-LC-1 expression at non-tumour sites and the clinical utility of these phenomena. The gene expression of KK-LC-1 was detected at the non-tumour sites including pyloric glands. The most detectable corpus/gland subset had a KK-LC-1 expression rate of 77% in the pyloric gland of the lower corpus where H. pylori preferentially exists. KK-LC-1 expression rates were 67% or 32% with or without intestinal metaplasia, which also induced by H. pylori, respectively. Consequently, KK-LC-1 would be detected at the pre-cancerous condition of the stomach, and may be a useful marker to predict gastric cancer.
Collapse
Affiliation(s)
- Takashi Fukuyama
- Division of Biomedical Research, Kitasato University Medical Center, Kitamoto, Japan.
| | - Nobue Futawatari
- Department of Surgery, Sagamihara National Hospital, Sagamihara, Japan
| | - Rui Yamamura
- Division of Biomedical Research, Kitasato University Medical Center, Kitamoto, Japan
| | - Taiga Yamazaki
- Division of Biomedical Research, Kitasato University Medical Center, Kitamoto, Japan
| | - Yoshinobu Ichiki
- Second Department of Surgery, University of Occupational and Environmental Health, Kitakyushu, Japan
| | - Akira Ema
- Department of Surgery, School of Medicine, Kitasato University, Sagamihara, Japan
| | - Hideki Ushiku
- Department of Surgery, School of Medicine, Kitasato University, Sagamihara, Japan.,Division of Surgery, Kitasato University Medical Center, Kitamoto, Japan
| | - Yatsushi Nishi
- Division of Surgery, Kitasato University Medical Center, Kitamoto, Japan
| | - Yoshihito Takahashi
- Department of Surgery, School of Medicine, Kitasato University, Sagamihara, Japan.,Division of Surgery, Kitasato University Medical Center, Kitamoto, Japan
| | - Toshikazu Otsuka
- Division of Gastroenterology, Kitasato University Medical Center, Kitamoto, Japan
| | - Hitoshi Yamazaki
- Division of Pathology, Kitasato University Medical Center, Kitamoto, Japan
| | - Wasaburo Koizumi
- Department of Gastroenterology, School of Medicine, Kitasato University, Sagamihara, Japan
| | | | - Noritada Kobayashi
- Division of Biomedical Research, Kitasato University Medical Center, Kitamoto, Japan
| |
Collapse
|
26
|
Yoshida Y, Naito M, Yamada T, Aisu N, Kojima D, Mera T, Tanaka T, Naito K, Yasumoto K, Kamigaki T, Gotoh S, Kodama S, Yamashita Y, Hasegawa S. Clinical Study on the Medical Value of Combination Therapy Involving Adoptive Immunotherapy and Chemotherapy for Stage IV Colorectal Cancer (COMVI Study). Anticancer Res 2017; 37:3941-3946. [PMID: 28668898 DOI: 10.21873/anticanres.11777] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2017] [Revised: 05/22/2017] [Accepted: 05/23/2017] [Indexed: 11/10/2022]
Abstract
BACKGROUND Adoptive immunotherapy for cancer has evolved through development of novel technologies for generating a large number of activated killer cells, such as αβ T-cells, γδ T-cells, and natural killer cells. There has been no prospective trial of combination therapy involving adoptive immunotherapy and first-line chemotherapy for stage IV colorectal cancer. The present pilot study aimed to evaluate the safety and feasibility of combination therapy involving adoptive immunotherapy and chemotherapy for stage IV colorectal cancer (COMVI study). PATIENTS AND METHODS The COMVI study was a prospective, single-arm pilot trial. Therapy in each 21-day treatment cycle involved XELOX (130 mg/m2 of oxaliplatin on day 1 plus 1,000 mg/m2 of capecitabine twice daily on days 1-14), bevacizumab (7.5 mg/kg on day 1), and αβ T-lymphocytes (over 5×109 on day 18) cultured ex vivo with an immobilized antibody to CD3 and interleukin-2. RESULTS The study included six patients (two men and four women) between June 2013 and September 2014. The median patient age was 68 years (range=55-75 years). The overall response rate was 83.3% [complete response in two (33.3%); partial response in three (50.0%); stable disease in one (16.7%); no cases of progressive disease]. The tumor volume reduction rate was 53% (range=38.0-100%). The median progression-free and overall survival durations were 567 and 966 days, respectively. Most adverse events were mild-to-moderate in intensity, and no grade 4 adverse events occurred in the six patients. Only one patient experienced grade 3 hypertension and ileus. Immunotherapy-associated toxicity was minimal in this study. CONCLUSION Combination therapy involving adoptive immunotherapy and chemotherapy for stage IV colorectal cancer is feasible and safe. Phase II prospective studies are needed to confirm the safety and efficacy of such chemoimmunotherapy.
Collapse
Affiliation(s)
- Yoichiro Yoshida
- Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | - Masayasu Naito
- Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | - Teppei Yamada
- Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | - Naoya Aisu
- Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | - Daibo Kojima
- Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | - Toshiyuki Mera
- Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | - Toshihiro Tanaka
- Division of Oncology, Hematology and Infectious Diseases, Department of Internal Medicine, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | | | | | | | | | - Shohta Kodama
- Department of Regenerative Medicine & Transplantation, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | - Yuichi Yamashita
- Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | - Suguru Hasegawa
- Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| |
Collapse
|
27
|
Ishii F, Yoshida Y, Yamauchi Y, Aisu N, Kojima D, Mera T, Kato D, Tanaka T, Naito K, Yasumoto K, Kamigaki T, Goto S, Hamada Y, Nimura S, Kodama S, Hasegawa S. Hepatectomy for Liver Metastases of Colorectal Cancer After Adoptive Chemoimmunotherapy Using Activated αβ T-cells. Anticancer Res 2017; 37:3933-3939. [PMID: 28668897 DOI: 10.21873/anticanres.11776] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2017] [Revised: 05/18/2017] [Accepted: 05/19/2017] [Indexed: 11/10/2022]
Abstract
BACKGROUND/AIM Various types of chemoimmunotherapies for malignant tumors have been reported. However, there are few reports on hepatectomy after chemoimmunotherapy. We evaluated the safety and efficacy of hepatectomy for patients with stage IV colorectal liver metastases (CLM) after chemoimmunotherapy using activated αβ T-cells. PATIENTS AND METHODS From June 2012 to December 2016, five patients who underwent hepatectomy after receiving capecitabine and oxaliplatin (XELOX) plus bevacizumab and ex vivo-expanded αβ T-lymphocytes as first-line chemoimmunotherapy were included. RESULTS The median age of the five patients (two men, three women) was 61.4 (range=56-75) years. The surgical procedure was partial hepatectomy in two, laparoscopic partial hepatectomy in two, and one case of partial hepatectomy with subsegmentectomy. There was no postoperative complication of Clavien-Dindo grade 3A or higher. One patient had multiple lung metastases. CONCLUSION Hepatectomy after chemoimmunotherapy using activated αβ T-cells for CLM can be performed safely.
Collapse
Affiliation(s)
- Fuminori Ishii
- Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | - Yoichiro Yoshida
- Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | - Yasushi Yamauchi
- Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | - Naoya Aisu
- Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | - Daibo Kojima
- Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | - Toshiyuki Mera
- Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | - Daisuke Kato
- Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | - Toshihiro Tanaka
- Division of Oncology, Hematology and Infectious Diseases, Department of Internal Medicine, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | | | | | | | | | - Yoshihiro Hamada
- Department of Pathology, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | - Satoshi Nimura
- Department of Pathology, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | - Shohta Kodama
- Department of Regenerative Medicine and Transplantation, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | - Suguru Hasegawa
- Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| |
Collapse
|
28
|
Nakamura D, Nishino M, Yasunaga M, Yanagawa K, Nakamura H, Matsuhiro Y, Yasumura K, Yasumoto K, Tanaka A, Mori N, Yano M, Egami Y, Shutta R, Tanouchi J. 3117Impact of neoatherosclerosis in lesions with in-stent restenosis evaluated by optical coherence tomography on mid-term outcome after plain old balloon angioplasty and drug coated balloon. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx504.3117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
29
|
Nakamura D, Nishino M, Yasunaga M, Yanagawa K, Nakamura H, Matsuhiro Y, Yasumura K, Yasumoto K, Tanaka A, Mori N, Yano M, Egami Y, Shutta R, Tanouchi J. P6115Difference of neoatherosclerosis pattern in lesions with in-stent restenosis among bare-metal, first and second generation drug-eluting stents: optical coherence tomography study. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx493.p6115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
30
|
Matsuhiro Y, Syutta R, Nakamura H, Yasumura K, Yasumoto K, Okamoto N, Tanaka H, Mori N, Nakamura D, Yano M, Makino N, Egami Y, Nisino M, Tanouti J. P5597Effect of number of connectors on vessel healing at proximal edge part after everolimus -eluting stent implantation using optical coherence tomography. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx493.p5597] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
31
|
Yoshida Y, Aisu N, Nagano H, Komono A, Kojima D, Mera T, Tanaka T, Naitoh K, Yasumoto K, Kamigaki T, Goto S, Hasegawa S. Immunotherapy using activated T cells with chemotherapy for metastatic colorectal cancer. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.4_suppl.767] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
767 Background: The programmed death-1 (PD-1), an inhibitory receptor expressed on activated T cells, is demonstrated to induce an immune-mediated response and play a critical role in tumor initiation and development. T cell activation induces effective antitumor immune response in cancer patients. Adoptive immunotherapy of cancer is evolving with the development of novel technologies that generate proliferation of large number of T cells. We evaluated the safety and efficacy of the combination of adoptive immunotherapy using αβ T cells with chemotherapy for metastatic colorectal cancer (mCRC). Methods: Seventeen patients with mCRC received XELOX + bevacizumab + ex vivo expanded αβ T lymphocytes as a first-line chemoimmunotherapy. Results: Median age of the 17 patients (6 men, 11 women) was 64 years (range:38–80). The T cell number was more than 5.0×109 for each infusion. Median progression-free survival was 15.2 months. Response rate was 80% (complete response (CR) = 23.5%, partial response (PR) = 47.1%, stable disease (SD) = 29.4% and progressive disease (PD) = 0%). Most adverse events were mild to moderate in intensity and immunotherapy-associated toxicity was minimal. Conclusions: Combination of adoptive αβ T cell immunotherapy with chemotherapy for mCRC is safe and effective.
Collapse
Affiliation(s)
- Yoichiro Yoshida
- Department of Gastroenterological Surgery, Fukuoka University School of Medicine, Fukuoka, Japan
| | - Naoya Aisu
- Department of Gastroenterological Surgery, Fukuoka University School of Medicine, Fukuoka, Japan
| | - Hideki Nagano
- Department of Gastroenterological Surgery, Fukuoka University School of Medicine, Fukuoka, Japan
| | - Akira Komono
- Department of Gastroenterological Surgery, Fukuoka University School of Medicine, Fukuoka, Japan
| | - Daibo Kojima
- Department of Gastroenterological Surgery, Fukuoka University School of Medicine, Fukuoka, Japan
| | - Toshiyuki Mera
- Department of Gastroenterological Surgery, Fukuoka University School of Medicine, Fukuoka, Japan
| | - Toshihiro Tanaka
- Division of Oncology, Hematology and Infectious Diseases, Department of Internal Medicine, Fukuoka University, Fukuoka, Japan
| | | | | | | | | | - Suguru Hasegawa
- Department of Gastroenterological Surgery, Fukuoka University School of Medicine, Fukuoka, Japan
| |
Collapse
|
32
|
Yoshida Y, Naito M, Yamada T, Aisu N, Daibo K, Mera T, Tanaka T, Naito K, Yasumoto K, Kamigaki T, Goto S, Yamashita Y, Hasegawa S. Adoptive Chemoimmunotherapy Using Activated αβ T Cells for Stage IV Colorectal Cancer. Anticancer Res 2016; 36:3741-3746. [PMID: 27354648] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2016] [Accepted: 05/12/2016] [Indexed: 06/06/2023]
Abstract
BACKGROUND/AIM Adoptive immunotherapy of cancer is evolving with the development of novel technologies that generate proliferation of large numbers of αβ and γδ T cells. We evaluated the safety and efficacy of the combination of adoptive immunotherapy using αβ T cells with chemotherapy for stage IV colorectal cancer (CRC). PATIENTS AND METHODS Fifteen patients with advanced or recurrent CRC received XELOX + bevacizumab + ex vivo expanded αβ T lymphocytes as a first-line chemoimmunotherapy. RESULTS Median age of the 15 patients (4 men, 11 women) was 65 years (range=49-80). Median progression-free survival was 21.3 months. Response rate was 80% (complete response (CR)=26.7%, partial response (PR)=53.3%, stable disease (SD)=20% and progressive disease (PD)=0%). Most adverse events were mild to moderate regarding their intensity and immunotherapy-associated toxicity was minimal. CONCLUSION Combination of adoptive αβ T cell immunotherapy with chemotherapy for stage IV CRC is feasible and safe.
Collapse
Affiliation(s)
- Yoichiro Yoshida
- Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | - Masayasu Naito
- Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | - Teppei Yamada
- Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | - Naoya Aisu
- Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | - Kojima Daibo
- Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | - Toshiyuki Mera
- Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | - Toshihiro Tanaka
- Division of Oncology, Hematology and Infectious Diseases, Department of Internal Medicine, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | | | | | | | | | - Yuichi Yamashita
- Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| | - Suguru Hasegawa
- Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan
| |
Collapse
|
33
|
Yoshida Y, Naito M, Yamada T, Aisu N, Kojima D, Mera T, Tanimura S, Tanaka T, Naitoh K, Yasumoto K, Kamigaki T, Goto S, Yamashita Y. Clinical study on medical value of adoptive immunotherapy with chemotherapy for stage IV colorectal cancer (COMVI study). J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.4_suppl.628] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
628 Background: Adoptive immunotherapy of cancer is evolving with the development of novel technologies for generating a large number of activated killer cells such as αβ T cells, γδ T cells, and natural killer (NK) cells. We conducted a pilot study to evaluate the safety and feasibility of the combination treatment of adoptive immunotherapy with chemotherapy for stage IV colorectal cancer. Methods: The COMVI study was a prospective and single-arm pilot trial. Therapy in each 21-day treatment cycle consisted of XELOX (130 mg/m2 of oxaliplatin on day 1 plus 1,000 mg/m2 of capecitabine twice daily on days 1–14), bevacizumab (7.5 mg/kg on day 1) and αβ T lymphocytes (over 5 ×109 on day 18) cultured ex vivo with an immobilized anti-CD3 antibody and interleukin-2. Results: A total of 6 patients were enrolled from June 2013 to September 2014. Baseline characteristics included a median age of 66 years (range: 55-75) for 2 men and 4women. Median PFS was 567 days. Overall response rate was 100 % (CR 33.3%, PR 66.7%, SD 0%, PD 0%). The tumor reduction rate was 53% (38.0–100%). The majority of adverse events were mild to moderate in intensity, and no grade 4 adverse events occurred in the 6 patients. Only one patient experienced grade 3 hypertension and ileus. Immunotherapy-associated toxicity was minimal in this study. Conclusions: The combination treatment of adoptive immunotherapy with chemotherapy for stage IV colorectal cancer is feasible and safe. Phase II prospective studies are warranted to confirm the safety and efficacy of this chemoimmunotherapy. Clinical trial information: UMIN000010908.
Collapse
Affiliation(s)
- Yoichiro Yoshida
- Department of Gastroenterological Surgery, Fukuoka University School of Medicine, Fukuoka, Japan
| | | | - Teppei Yamada
- Department of Gastroenterological Surgery, Fukuoka University School of Medicine, Fukuoka, Japan
| | - Naoya Aisu
- Department of Gastroenterological Surgery, Fukuoka University School of Medicine, Fukuoka, Japan
| | - Daibo Kojima
- Department of Gastroenterological Surgery, Fukuoka University School of Medicine, Fukuoka, Japan
| | - Toshiyuki Mera
- Department of Gastroenterological Surgery, Fukuoka University School of Medicine, Fukuoka, Japan
| | - Syu Tanimura
- Department of Gastroenterological Surgery, Fukuoka University School of Medicine, Fukuoka, Japan
| | - Toshihiro Tanaka
- Division of Oncology, Hematology and Infectious Diseases, Department of Internal Medicine, Fukuoka University, Fukuoka, Japan
| | | | | | | | | | - Yuichi Yamashita
- Department of Gastroenterological Surgery, Fukuoka University School of Medicine, Fukuoka, Japan
| |
Collapse
|
34
|
So T, Mitsueda R, Miyata T, Sekimura A, Yoshimatsu T, Nose N, Itoh H, Nakano S, Yasumoto K. Pulmonary dirofilariasis in a 59-year-old man. J Surg Case Rep 2014; 2014:rju082. [PMID: 25168854 PMCID: PMC4147646 DOI: 10.1093/jscr/rju082] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
We present a case of a human pulmonary dirofilariasis in a 59-year-old man. At the medical examination, a chest computed tomography (CT) revealed a mass, measuring 18 × 15 mm in diameter, with an irregular margin on the bottom of the right lower lobe. We could not neglect the possibility of a primary lung cancer, and therefore, a lung partial resection was performed under video-assisted thoracoscopic surgery. The intra-operative pathological findings revealed inflammatory granuloma with coagulation necrosis and no malignant cells. The permanent pathological examination showed occlusion of the peripheral pulmonary artery by worms and formation of a necrotic mass surrounded by reactive inflammation and hemorrhage. Human pulmonary dirofilariasis is an extremely rare zoonotic infection, and sometimes it is difficult to distinguish it from a primary lung cancer on radiographic findings.
Collapse
Affiliation(s)
- Tetsuya So
- Department of Thoracic Surgery, Shinkomonji Hospital, Kitakyushu 800-0057, Japan
| | - Reiko Mitsueda
- Department of Thoracic Surgery, Fukuoka-Wajiro Hospital, Fukuoka 811-0213, Japan
| | - Takeaki Miyata
- Department of Thoracic Surgery, Fukuoka-Wajiro Hospital, Fukuoka 811-0213, Japan
| | - Atsushi Sekimura
- Department of Thoracic Surgery, Shintakeo Hospital, Takeo City, Saga 843-0024, Japan
| | - Takashi Yoshimatsu
- Department of Thoracic Surgery, Shintakeo Hospital, Takeo City, Saga 843-0024, Japan
| | - Naohiro Nose
- Department of Thoracic Surgery, Shinyukuhashi Hospital, Yukuhashi City, Fukuoka 824-0026, Japan
| | - Hiroshi Itoh
- Department of Pathology, Shinkomonji Hospital, Kitakyushu 800-0057, Japan
| | - Shigeo Nakano
- Department of Pathology, Shinkomonji Hospital, Kitakyushu 800-0057, Japan
| | - Kosei Yasumoto
- Department of Thoracic Surgery, Shinkomonji Hospital, Kitakyushu 800-0057, Japan
| |
Collapse
|
35
|
Yoshimi M, Kitamura Y, Isshiki S, Saito T, Yasumoto K, Terachi T, Yamagishi H. Variations in the structure and transcription of the mitochondrial atp and cox genes in wild Solanum species that induce male sterility in eggplant (S. melongena). Theor Appl Genet 2013; 126:1851-9. [PMID: 23604528 DOI: 10.1007/s00122-013-2097-6] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/12/2012] [Accepted: 04/02/2013] [Indexed: 05/05/2023]
Abstract
In order to determine the molecular basis of cytoplasmic male sterility (CMS) in alloplasmic lines of eggplant, the genomic structures and transcription patterns of mitochondrial ATP synthase subunit (atp) and cytochrome oxidase subunit (cox) genes were studied for wild and cultivated eggplants. Alloplasmic eggplant lines with cytoplasms of wild Solanum species showing either anther indehiscent type of CMS or non-pollen production type of CMS were studied with the cultivated eggplant Solanum melongena, used as a control. Southern hybridization of the mitochondrial genes indicated the difference between the two types of CMS and showed complete identity within each type. The cytoplasmic patterns of all wild species differed from that of the cultivated eggplant. Thus, the cytoplasm of the six wild eggplants and the one cultivated eggplant was classified into three groups. Male sterile plants of both types of CMS showed novel transcription patterns of atp1, whereas a different transcription pattern of cox2 was observed only in the anther indehiscent type. Based on these differences, we determined the DNA sequences of about a 4 kbp segment in the atp1 region. Although the coding and 3' flanking regions were almost identical among the cytoplasms, the 5' flanking region was completely different and novel open reading frames (orfs) were found for each of the CMS types and the cultivated eggplant. The cytoplasm of Solanum kurzii inducing the anther indehiscent type CMS had orf312, and those of Solanum aethiopicum and Solanum grandifolium of non-pollen production type CMS had orf218. The correspondence between the transcription patterns of these orfs and phenotypic expression of male sterility strongly suggests that these orfs are causal genes for each type of CMS.
Collapse
Affiliation(s)
- M Yoshimi
- Faculty of Life Sciences, Kyoto Sangyo University, Kamigamo, Kita, Kyoto 603-8555, Japan
| | | | | | | | | | | | | |
Collapse
|
36
|
Osaki T, Yasumoto K. [Clinical significance of micrometastases in the lymph nodes of patients with resectable lung cancer]. Nihon Geka Gakkai Zasshi 2013; 114:28-33. [PMID: 23457942] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
Clinical evaluation of micrometastases in the lymph nodes of lung cancer patients is not currently recommended in guidelines because of several different results concerning their prevalence and prognostic implications. However, a recent large, prospective, multicenter clinical study has shown a significant prognostic impact of micrometasteses in the lymph nodes of patients with resectable lung cancer; therefore, the clinical significance of micrometastases as predictive markers of recurrence and prognosis has begun to be clarified. From the viewpoint of surgery for lung cancer, sentinel node navigation surgery, segmentectomy, and individualized therapies such as adjuvant chemotherapy are expected to be developed. In the near future, standardization and improvement of the efficiency of diagnostic procedures will be necessary in common clinical practice. Recently, minimal residual cancer cell research, such as circulating tumor cells in the peripheral blood and disseminated tumor cells in the bone marrow, has made good progress. As research in this field continues, it is expected that the mechanism of metastasis and novel therapeutic strategies targeting minimal residual cancer cells will become better understood.
Collapse
|
37
|
Shigematsu Y, Hanagiri T, Shiota H, Kuroda K, Baba T, Ichiki Y, Yasuda M, Uramoto H, Takenoyama M, Yasumoto K, Tanaka F. Immunosuppressive effect of regulatory T lymphocytes in lung cancer, with special reference to their effects on the induction of autologous tumor-specific cytotoxic T lymphocytes. Oncol Lett 2012. [PMID: 23205074 DOI: 10.3892/ol.2012.815] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Abstract
It is not easy to induce cytotoxic T lymphocytes (CTLs) against cancer in in vitro culture. Regulatory T cells (Tregs) are considered to play a pivotal role in tumor immune escape. In this study, we analyzed the distribution of Tregs among tumor-infiltrating lymphocytes (TILs), regional lymph node lymphocytes (RLNLs) and peripheral blood lymphocytes (PBLs) in patients with lung cancer, and analyzed the effect of Tregs on the induction of CTLs in vitro. A total of 84 patients with non-small cell lung cancer underwent surgery between January 2003 and December 2004. The TILs, RLNLs and PBLs from these patients were subjected to a comparison analysis. The proportion of CD4(+)CD25(+)Foxp3(+) cells in these lymphocytes was determined by flow cytometry. The effects of Tregs on the induction of CTLs was analyzed by the depletion of Tregs in mixed lymphocyte-tumor cell culture (MLTC). The average proportions of Tregs in the TILs, RLNLs and PBLs were 10.4±9.5, 4.4±2.4 and 2.8±2.1%, respectively. The proportion of Tregs in the RLNLs was significantly higher than that in the PBLs (P<0.001); furthermore, TILs contained a larger number of Tregs than RLNLs (P=0.034). These Tregs substantially suppressed the induction of CTLs against autologous tumor cells. The depletion of Tregs in the MLTC resulted in the successful induction of CTLs. Tregs were found at a higher frequency in the TILs and RLNLs than in the PBLs in lung cancer patients. Since Tregs inhibited the induction of CTLs, the depletion of Tregs may represent a new therapeutic strategy for lung cancer patients.
Collapse
Affiliation(s)
- Yoshiki Shigematsu
- Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Yahatanishi 807-8555, Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Yasumoto K, So T, Nose N, Yoshimatsu T, Tomiyama M, Maekawa R. Induction of cellular immune response against autologous tumor cells by vaccination with autologous tumor lysate-pulsed dendritic cells. Lung Cancer 2012. [DOI: 10.1016/j.lungcan.2012.05.047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
39
|
Ichiki Y, Hanagiri T, Takenoyama M, Baba T, Nagata Y, Mizukami M, So T, Sugaya M, Yasuda M, Uramoro H, Yasumoto K. Differences in sensitivity to tumor-specific CTLs between primary and metastatic esophageal cancer cell lines derived from the same patient. Surg Today 2012; 42:272-9. [PMID: 22234743 DOI: 10.1007/s00595-011-0083-7] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2010] [Accepted: 03/07/2011] [Indexed: 10/14/2022]
Abstract
PURPOSE MHC antigens and adhesion molecules, such as the intracellular adhesion molecule (ICAM-I), play an important role in cellular immune response. We examined the expression patterns of these molecules in both primary and metastatic esophageal carcinoma cells from the same patient and evaluated the cellular immune responses against these cells. MATERIALS AND METHODS In the esophageal cancer patient (H122), tumor cell lines were established from primary and subcutaneous metastatic lesions. We compared the expression of cell surface molecules on the metastatic tumor cell line (H122SC) with that on the primary tumor cell line (H122ESO) using flow cytometry. Moreover, we analyzed the differences in cellular immune responses against these cell lines, which expressed similar levels of the Tara antigen, using the Tara antigen-specific CTL clone. RESULTS H122SC ICAM-1 expression was significantly lower in H122ESO, and the Tara antigen-specific CTL clone produced lower levels of TNF in response to H122SC than H122ESO. ICAM-1 transfection into the H122SC rendered these cells as sensitive to the CTL clone as the H122ESO. CONCLUSION The metastatic tumor cells displayed lower regulated ICAM-1 expression levels and were less sensitive to specific CTLs. ICAM-1 downregulation may be one mechanism by which tumor cells escape immunologic surveillance.
Collapse
Affiliation(s)
- Yoshinobu Ichiki
- Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
So T, Uramoto H, Hanagiri T, Takenoyama M, Ono K, So T, Yoshimatsu T, Yasumoto K. Successful treatment of lung adenocarcinoma in an 18-year-old man. Gen Thorac Cardiovasc Surg 2012; 59:616-8. [PMID: 22231790 DOI: 10.1007/s11748-010-0730-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2010] [Accepted: 10/18/2010] [Indexed: 10/17/2022]
Abstract
Primary lung cancer is an extremely rare neoplasm in young adults. We report a case of a primary lung adenocarcinoma in an 18-year-old man who presented for examination of a solitary nodule located in the right lower lobe of the lung. A right lower lobectomy was performed with an incomplete resection because of pleural dissemination (pT4N2M0 stage IIIB adenocarcinoma). Intrathoracic chemotherapy (cisplatin, 50 mg/body) was administered initially, followed by systemic chemotherapy (carboplatin + paclitaxel). A bronchopleural fistula occurred 2 months postoperatively and was successfully treated with conservative therapy, including thoracic drainage, intrathoracic fibrin glue administration, and transbronchial superglue administration. Thereafter, a total of five courses of systemic chemotherapy with minor changes in the administration regimen were performed. The patient was alive and with no evidence of recurrence at his 5-year follow-up.
Collapse
Affiliation(s)
- Tetsuya So
- Department of Thoracic Surgery, Shinkomonji Hospital, 2-5 Dairishinmachi, Moji-ku, Kitakyushu 800-0057, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
41
|
Abstract
Objectives: This study investigated the clinical features of patients with complete resection of thymic carcinoma. Patients and Methods: The clinical records from 11 patients who underwent a complete resection of thymic carcinoma were retrospectively reviewed. Results: Twelve of 22 patients underwent a resection (a complete resection in 11 and an incomplete in 1). Six of the 11 patients with complete had confirmed recurrent tumors. The 5-year survival rate was 45.4%, and the median survival time was 50.6 months. The patients who underwent complete resection showed significantly better prognosis than cases with incomplete resection and inoperable cases ( p = 0.048). Three of the 6 patients had a recurrence within 1 year. Frequent sites of recurrence were the pleura, pericardium, and lung. Conclusions: A complete resection improved the prognosis of thymic carcinoma. Further prospective studies regarding postoperative adjuvant therapy are necessary to prevent local recurrence after a surgical resection for thymic carcinoma.
Collapse
Affiliation(s)
- M. Yasuda
- Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
| | - T. Hanagiri
- Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
| | - S. Oka
- Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
| | - H. Uramoto
- Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
| | - M. Takenoyama
- Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
| | - K. Yasumoto
- Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
| |
Collapse
|
42
|
Iwata T, Sugio K, Uramoto H, Yamada S, Onitsuka T, Nose N, Ono K, Takenoyama M, Oyama T, Hanagiri T, Yasumoto K. Detection of EGFR and K-ras mutations for diagnosis of multiple lung adenocarcinomas. Front Biosci (Landmark Ed) 2011; 16:2961-9. [PMID: 21622214 DOI: 10.2741/3891] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The incidence of multiple primary lung adenocarcinoma (MPLA) is increasing, and it is important to distinguish MPLA from intrapulmonary metastasis (IPM) in order to determine the therapeutic strategy. However, there is no reliable method to differentiate between the two. The purpose of this study was to distinguish MPLA from IPM based on the gene status of EGFR and K-ras and the morphological Noguchi classification system. Sixty-eight tumors from 34 cases of clinical MPLA were evaluated. Of them, 11 cases (32.4%) were diagnosed as biological MPLA (bMPLA) by EGFR/K-ras mutation analyses, and 12 cases (35.3%) by morphological analysis. In all, 23 of the 34 cases (67.6%) were diagnosed as bMPLA. The remaining 11 cases were diagnosed as biological IPM (bIPM). The 5-year survival rates of bMPLA and bIPM were 90.9% and 63.6%, respectively (p=0.04). These findings suggest that the combination method including gene mutation and morphological analysis can guide treatment decisions and that there is a need for systemic chemotherapy, and surveillance monitoring.
Collapse
Affiliation(s)
- Teruo Iwata
- Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Hanagiri T, Sugaya M, Takenaka M, Oka S, Baba T, Shigematsu Y, Nagata Y, Shimokawa H, Uramoto H, Takenoyama M, Yasumoto K, Tanaka F. Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer. Lung Cancer 2011; 74:112-7. [PMID: 21397974 DOI: 10.1016/j.lungcan.2011.02.001] [Citation(s) in RCA: 52] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2010] [Revised: 02/03/2011] [Accepted: 02/06/2011] [Indexed: 11/18/2022]
Abstract
PURPOSE This study investigated the preoperative serum levels of CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer. SUBJECTS This study evaluated 341 patients who had undergone a complete resection for stage I NSCLC between 2002 and 2008. RESULTS The patients included 193 males and 148 females. The mean age of the patients was 69.2 years (range: 19-88). The histological types included 264 adenocarcinomas, 56 squamous cell carcinomas, 11 large cell carcinomas, and 10 other types of carcinoma. A pneumonectomy was performed in 2 patients, a bilobectomy in 7, a lobectomy in 255, a segmentectomy in 46, and partial resection of the lung in 31 patients. The positive rates for CYFRA 21-1 in the adenocarcinoma and squamous cell carcinoma patients were 33.3% and 76.8%, respectively. The positive rates for CEA in adenocarcinoma and squamous cell carcinoma patients were 23.8% and 26.8%, respectively. The 5-year survival rate after surgery in the normal CYFRA 21-1 group and the high CYFRA 21-1 groups were 92.8% and 75.4%, respectively, in the patients with stage I NSCLC. There was a significant difference between the 2 groups (p<0.0001). The 5-year survival rate according to the serum level of CEA in the patients with stage I NSCLC were 88.3% for the normal group and 76.3% for the high group. In a multivariate analysis using the variables found to be significant prognostic factors in univariate analysis, a high CYFRA 21-1 level was found to be a significant independent prognostic factor (95% confidence interval 1.213-5.442, p=0.014). CONCLUSION A high preoperative CYFRA 21-1 level was a significant independent prognostic factor in patients with stage I NSCLC. The patients with a high CYFRA 21-1 level should carefully followed-up to rule out occult metastasis. Further clinical studies will be necessary to evaluate the efficacy of adjuvant therapy for the patients selected according to this criterion.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Antigens, Neoplasm/genetics
- Antigens, Neoplasm/metabolism
- Biomarkers, Tumor/metabolism
- Carcinoma, Non-Small-Cell Lung/diagnosis
- Carcinoma, Non-Small-Cell Lung/mortality
- Carcinoma, Non-Small-Cell Lung/pathology
- Carcinoma, Non-Small-Cell Lung/physiopathology
- Disease Progression
- Female
- Humans
- Keratin-19/genetics
- Keratin-19/metabolism
- Lung Neoplasms/diagnosis
- Lung Neoplasms/mortality
- Lung Neoplasms/pathology
- Lung Neoplasms/physiopathology
- Male
- Middle Aged
- Neoplasm Staging
- Preoperative Care
- Prognosis
- Receptors, Cell Surface/genetics
- Receptors, Cell Surface/metabolism
- Survival Analysis
Collapse
Affiliation(s)
- Takeshi Hanagiri
- Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Yahatanishi, Iseigaoka 1-1, Yahatanishi-ku, Kitakyushu 807, Japan.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Moon SD, Ohguri T, Imada H, Yahara K, Yamaguchi S, Hanagiri T, Yasumoto K, Yatera K, Mukae H, Terashima H, Korogi Y. Definitive radiotherapy plus regional hyperthermia with or without chemotherapy for superior sulcus tumors: A 20-year, single center experience. Lung Cancer 2011; 71:338-43. [DOI: 10.1016/j.lungcan.2010.06.007] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2010] [Revised: 06/10/2010] [Accepted: 06/10/2010] [Indexed: 10/19/2022]
|
45
|
Ono K, Takenaka M, Yokoyama E, Oka S, Baba T, So T, So T, Uramoto H, Takenoyama M, Hanagiri T, Yasumoto K. [Clinical analysis of esophageal cancer associated with other primary cancers]. Kyobu Geka 2011; 64:93-98. [PMID: 21387611] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
This study aims to investigate the therapeutic and prognostic implications of esophageal cancer in patients with other primary cancer. Between April 1992 and December 2008, in 83 patients underwent surgery for esophageal cancer at our department. Among them, 24 patients (28.9%) had medical history of additional primary cancer. There were 16 metachronous cancers and 8 synchronous cancers. Six patients had antecedent other primary cancers, and subsequent primary cancers developed in 10 patients. The other primary cancers included head and neck cancer in 8 patients, gastric cancer in 8, lung cancer in 6, colorectal cancer in 3, and other cancer in 3. The patients with other primary cancers were both heavy smokers and heavy drinkers in comparison to those without other primary cancers. The post-operative 5-year survival rate in patients with subsequent cancers, antecedent cancers, and synchronous cancers were 100%, 70.0%, and 46.9%. The 5-year survival rate was 33.4% in patients without other primary cancers. A high incidence of multiple primary cancers was observed in patients with esophageal carcinoma but the prognosis of these patients with metachronous cancers are better than that of patient with synchronous cancers and patients without other primary cancers. Post-operative follow up is considered to be necessary for early detection of multiple occurrences of carcinoma, especially in the upper aerodigestive tract.
Collapse
Affiliation(s)
- Kenji Ono
- Second Department of Surgery, University of Occupational and Environmental Health, Kitakyushu, Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Iwanami T, Uramoto H, Baba T, Takenaka M, Yokoyama E, Oka S, So T, Ono K, So T, Takenoyama M, Hanagiri T, Iwata T, Inoue M, Yasumoto K. [Treatment recommendations for adrenal metastasis of non-small cell lung cancer]. Kyobu Geka 2010; 63:1101-1108. [PMID: 21174656] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
To evaluate the optimum treatment strategy for metastatic adrenal tumors derived from non-small cell lung cancer (NSCLC), we retrospectively analyzed 17 consecutive cases (8 resection cases: 4 synchronous and 4 metachronous: 9 non-resection cases: 3 synchronous and 6 metachronous) who received surgical resection for NSCLC. The patients included 12 males and 5 females with a mean age of 63.9 years. Of these, 9, 3, 2, 2, and 1 patient (s) were diagnosed as having adenocarcinoma, squamous cell carcinoma, pleomorphic carcinoma, large cell carcinoma, and adenosquamous cell carcinoma, respectively. The mean interval after lung resection and treatment of metachronous adrenal metastasis was 9.9 months. The mean time to progression from treatment of metachronous adrenal metastasis to disease progression was 8.9 months. A survival analysis showed no significant prognostic difference between the patient age, gender, pathological stage, synchronous/metachronous classification, CEA, and site of metastases. However, patients who received an adrenalectomy had a more favorable prognosis. The 2-year survival of patients following resection versus those who did not undergo a resection for adrenal metastasis was 62.5 and 22.8%, respectively. These data indicate that metastatic adrenal tumors should be resected if the patient can tolerate surgery after appropriate selection.
Collapse
Affiliation(s)
- Takashi Iwanami
- Department of Thoracic Surgery, Niigata Rosai Hospital, Joetsu, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Shimokawa H, Uramoto H, Onitsuka T, Chundong G, Hanagiri T, Oyama T, Yasumoto K. Overexpression of MACC1 mRNA in lung adenocarcinoma is associated with postoperative recurrence. J Thorac Cardiovasc Surg 2010; 141:895-8. [PMID: 21093878 DOI: 10.1016/j.jtcvs.2010.09.044] [Citation(s) in RCA: 77] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/11/2010] [Revised: 08/27/2010] [Accepted: 09/10/2010] [Indexed: 11/26/2022]
Abstract
OBJECTIVE The purpose of this study was to clarify the role and clinical significance of metastasis associated in colon cancer 1 in resected stage I non-small cell lung cancers. METHODS Tumor specimens were collected from 146 consecutive patients who underwent a complete resection for stage I lung adenocarcinoma from 1998 to 2007 at the University of Occupational and Environmental Health. We analyzed the expression of metastasis associated in colon cancer 1 mRNA of primary lung adenocarcinomas by real-time reverse transcriptase-polymerase chain reaction. RESULTS The average postoperative observation period was 49.4 months. Thirteen (8.9%) of 146 patients had recurrences after surgery. Overexpression of metastasis associated in colon cancer 1 mRNA was identified in 62 patients (42.5%). Metastasis associated in colon cancer 1 was overexpressed in 9 (69.2%) of 13 patients and 53 (39.9%) of 133 patients with and without recurrence, respectively (P = .004). The median metastasis associated in colon cancer 1 copy number was 3.0 and 1.4 in patients with and without tumor recurrence, respectively. Metastasis associated in colon cancer 1 overexpression was associated with poorer disease-free survival according to the survival analysis (P = .033). CONCLUSIONS Metastasis associated in colon cancer 1 gene overexpression may be a useful marker for predicting postoperative recurrence in patients with lung adenocarcinoma after surgery.
Collapse
Affiliation(s)
- Hidehiko Shimokawa
- Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
| | | | | | | | | | | | | |
Collapse
|
48
|
Ichiki Y, Hanagiri T, Baba T, So T, Ono K, Uramoto H, So T, Takenoyama M, Yasumoto K. Limited pulmonary resection for peripheral small-sized adenocarcinoma of the lung. Int J Surg 2010; 9:155-9. [PMID: 21093617 DOI: 10.1016/j.ijsu.2010.10.011] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2010] [Revised: 09/14/2010] [Accepted: 10/24/2010] [Indexed: 10/18/2022]
Abstract
BACKGROUND It was recently reported that a limited pulmonary resection (segmentectomy or wedge resection) was not inferior to a lobectomy in the management of peripheral small-sized adenocarcinoma (tumor ≦ 20 mm) of the lung. METHODS We retrospectively analyzed patients undergoing a lobectomy (n = 114) and a limited resection (n = 35) for peripheral small-sized adenocarcinoma of the lung during a 7-year period from April 2001 to March 2008. Our criteria for the limited resection of lung cancer were as follows: (1) adenocarcinoma of 10 mm or less in diameter and (2) adenocarcinoma of 11-20 mm in diameter, in which the ratio of the ground glass opacity is 50% or more, without pleural indentation on computed tomography. Additionally, the frozen sections of the tumors were intraoperatively diagnosed as Noguchi type A or B. The survival and clinical outcomes were analyzed. RESULTS The 5-year survival rates of the lobectomy group and limited resection groups were 89.2% and 100%, respectively. No recurrence was seen in the limited resection group. CONCLUSIONS Our results suggest that our criteria for limited resection were adequate for the management of small-sized adenocarcinoma of the lung.
Collapse
Affiliation(s)
- Yoshinobu Ichiki
- Second Department of Surgery, University of Occupational and Environmental Health, School of Medicine, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Uramoto H, Nakanishi R, Nagashima A, Uchiyama A, Inoue M, Osaki T, Yoshimatsu T, Sakata H, Nakanishi K, Yasumoto K. A randomized phase II trial of adjuvant chemotherapy with bi-weekly carboplatin plus paclitaxel versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer. Anticancer Res 2010; 30:4695-4699. [PMID: 21115926] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
BACKGROUND The benefits of adjuvant chemotherapy for completely resected non-small cell lung cancer (NSCLC) have been demonstrated using mainly cisplatin (CDDP)-based chemotherapeutic regimens. However, treatment-related deaths sometimes occur. Therefore, the development of a safer regimen is necessary. PATIENTS AND METHODS The patients were randomized to either carboplatin (CBDCA) area under the curve (AUC) 3 and paclitaxel (PTX) 90 mg/m(2) (PCb arm) or CBDCA (AUC3) plus gemcitabine (GEM) (1000 mg/m(2)) (GCb arm) every 2 weeks for 8 cycles after surgery. The primary endpoint was the compliance with the regimen, while the secondary endpoints were safety and toxicity. RESULTS A total of 75 patients were enrolled in a multi-institutional study. Twenty-one out of 39 patients (54%) in the PCb arm and 25 of 36 patients (69%) in the GCb arm completed 8 cycles, and 59% in the PCb arm and 81% in the GCb arm completed ≥6 cycles. The predominant toxicity was neutropenia. Non-hematological adverse effects were infrequent and no treatment-related death was registered. The estimated disease-free survival and overall survival at 2 years were 70.8% and 66.3% in the PCb and 91.4% and 79.1% in the GCb arm, respectively. CONCLUSION This adjuvant bi-weekly scheduled chemotherapy resulted in good compliance in both arms, and the regimen was feasible, with acceptable levels of toxicity in completely resected Japanese NSCLC patients. Therefore, these regimens represent a new treatment option suitable for outpatients with completely resected NSCLC.
Collapse
MESH Headings
- Adenocarcinoma/drug therapy
- Adenocarcinoma/pathology
- Adenocarcinoma/surgery
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Carboplatin/administration & dosage
- Carcinoma, Large Cell/drug therapy
- Carcinoma, Large Cell/pathology
- Carcinoma, Large Cell/surgery
- Carcinoma, Non-Small-Cell Lung/drug therapy
- Carcinoma, Non-Small-Cell Lung/pathology
- Carcinoma, Non-Small-Cell Lung/surgery
- Carcinoma, Squamous Cell/drug therapy
- Carcinoma, Squamous Cell/pathology
- Carcinoma, Squamous Cell/surgery
- Chemotherapy, Adjuvant
- Deoxycytidine/administration & dosage
- Deoxycytidine/analogs & derivatives
- Female
- Humans
- Lung Neoplasms/drug therapy
- Lung Neoplasms/pathology
- Lung Neoplasms/surgery
- Male
- Middle Aged
- Neoplasm Staging
- Paclitaxel/administration & dosage
- Prospective Studies
- Survival Rate
- Treatment Outcome
- Gemcitabine
Collapse
Affiliation(s)
- Hidetaka Uramoto
- Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Yamamoto C, Basaki Y, Kawahara A, Nakashima K, Kage M, Izumi H, Kohno K, Uramoto H, Yasumoto K, Kuwano M, Ono M. Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations. Cancer Res 2010; 70:8715-25. [PMID: 20959484 DOI: 10.1158/0008-5472.can-10-0043] [Citation(s) in RCA: 125] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Gefitinib (Iressa) and erlotinib (Tarceva), which target the epidermal growth factor receptor (EGFR), are approved for treatment of patients with advanced non-small cell lung cancer (NSCLC). Patients whose tumors harbor mutations in the EGFR gene, including delE746-A750 in exon 19 and L858R in exon 21, may benefit in particular from gefitinib treatment. However, acquired resistance to gefitinib has been a serious clinical problem, and further optimization is needed for application of EGFR-targeted drugs in lung cancer patients. In this study, we established gefitinib-resistant NSCLC cells from PC-9 cell line, which harbors the delE746-A750 mutation, by exposing the cell line to gefitinib for over 7 months. Gefitinib-resistant PC-9/GEFs cell lines showed a marked downregulation of PTEN expression and increased Akt phosphorylation. In revertant, gefitinib-sensitive clones (PC-9/Rev) derived from PC-9/GEF1-1 and PC-9/GEF2-1, PTEN expression, as well as sensitivity to gefitinib and erlotinib, was restored. Knockdown of PTEN expression using small interfering RNA specific for PTEN in PC-9 cells resulted in drug resistance to gefitinib and erlotinib. Nuclear translocation of the EGR1 transcription factor, which regulates PTEN expression, was shown to be suppressed in resistant clones and restored in their revertant clones. Reduced PTEN expression was also seen in tumor samples from a patient with gefitinib-refractory NSCLC. This study thus strongly suggests that loss of PTEN expression contributes to gefitinib and erlotinib resistance in NSCLC. Our findings reinforce the therapeutic importance of PTEN expression in the treatment of NSCLC with EGFR-targeted drugs.
Collapse
Affiliation(s)
- Chizuko Yamamoto
- Department of Pharmaceutical Oncology and Laboratory of Molecular Cancer Biology, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|